[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8088
6. Fewou SN, Ramakrishnan H, Büssow H, Gieselmann V, Eckhardt M: Down-regulation of polysialic acid is required for efficient myelin formation. J Biol Chem; 2007 Jun 1;282(22):16700-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oligodendrocyte precursor cells modify the neural cell adhesion molecule (NCAM) by the attachment of polysialic acid (PSA).
  • Upon further differentiation into mature myelinating oligodendrocytes, however, oligodendrocyte precursor cells down-regulate PSA synthesis.
  • In these mice, postnatal down-regulation of PSA in oligodendrocytes was abolished.
  • Most NCAM-120, the characteristic NCAM isoform in oligodendrocytes, carried PSA in the transgenic mice at all stages of postnatal development.
  • The permanent expression of PSA-NCAM in oligodendrocytes led to a reduced myelin content in the forebrains of transgenic mice during the period of active myelination and in the adult animal.
  • Thus, down-regulation of PSA during oligodendrocyte differentiation is a prerequisite for efficient myelination by mature oligodendrocytes.
  • Furthermore, myelin of transgenic mice exhibited structural abnormalities like redundant myelin and axonal degeneration, indicating that the down-regulation of PSA is also necessary for myelin maintenance.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17420257.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myelin Basic Protein; 0 / Myelin Proteolipid Protein; 0 / Nerve Tissue Proteins; 0 / Neural Cell Adhesion Molecules; 0 / Plp1 protein, mouse; 0 / Protein Isoforms; 0 / Sialic Acids; 0 / polysialic acid; EC 2.4.99.- / Sialyltransferases
  •  go-up   go-down


7. Roscigno M, Scattoni V, Freschi M, Raber M, Angiolilli D, Galosi A, Lacetera V, Montironi R, Muzzonigro G, Deho F, Feroldi L, Deiana G, Chinaglia D, Montorsi F, Da Pozzo LF: Diagnosis of high-grade prostatic intraepithelial neoplasia: the impact of the number of biopsy cores at initial sampling on cancer detection after a saturation re-biopsy. Arch Ital Urol Androl; 2010 Dec;82(4):242-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of high-grade prostatic intraepithelial neoplasia: the impact of the number of biopsy cores at initial sampling on cancer detection after a saturation re-biopsy.
  • OBJECTIVES: To evaluate factors that may predict prostate cancer (PCa) detection after initial diagnosis of high-grade prostatic intraepithelial neoplasia (HGPIN) on 6-24 cores prostatic biopsies (PBx).
  • MATERIAL AND METHODS: We retrospectively evaluated 193 patients submitted from 1998 to 2007 to prostate re-biopsy after initial HGPIN diagnosis in three urologic departments.
  • HGPIN diagnosis was obtained on initial systematic PBx with 6 to 24 random cores.
  • PSA (6.7 vs 8.5 ng/ml; p = 0.029) and age (64 vs 68 years; p = 0.005) were significantly higher in patients with PCa at re-biopsy.
  • At multivariable analysis, PSA value (p = 0.007; HR:1.18), prostate volume (p = 0.01; HR:0.966), age (p < 0.001; HR:1.15), pHGPIN (p = 0.003; HR:2.97) and < or = 12-core initial biopsy (p = 0.012; HR:3.62) were independent predictors of PC detection.
  • On the contrary, in patients with > 12-core initial biopsy, higher PSA values and lower prostate volume were independent predictors of PC detection.
  • CONCLUSIONS: PCa detection on saturation re-biopsy after initial diagnosis of HGPIN is significantly higher in patients submitted to < or = 12-core than those submitted to > 12-core initial PBx.
  • In patients with > 12-core initial biopsy, higher PSA values and lower prostate volume was associated to an increased risk of PCa detection at re-biopsy.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21341572.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer; 2007 Jul 27;7:142
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) metastatic disease by radionucleotide bone imaging; or (3) elevated prostate specific antigen (PSA).
  • RESULTS: Characteristics of 22 patients enrolled included: median age 73.5 years (range, 65-80); median Karnofsky Performance Status 90 (range 70-100); median hemoglobin 12.1 g/dl (range, 10.0-14.3); median PSA 218.3 ng/ml (range, 9-5754).
  • Bone scan improvement and PSA decline was seen in 1 patient (5%, 95% CI 0.1-25%).
  • Five of 22 patients experienced > or = 50 % decline in PSA (23%, 95% CI 8-45%).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1918-25 [11106683.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 11):76-83; discussion 92-100 [11236032.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S [11560969.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1107-14 [12569613.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2478-86 [12855621.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1756-64 [8656243.001]
  • [Cites] Nat Med. 1999 Mar;5(3):280-5 [10086382.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64 [16163160.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2506-13 [10561316.001]
  • (PMID = 17662137.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P50 CA92131
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ PMC1941739
  •  go-up   go-down


9. Ohwaki K, Endo F, Muraishi O, Hiramatsu S, Yano E: Relationship between prostate-specific antigen and hematocrit: does hemodilution lead to lower PSA concentrations in men with a higher body mass index? Urology; 2010 Mar;75(3):648-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between prostate-specific antigen and hematocrit: does hemodilution lead to lower PSA concentrations in men with a higher body mass index?
  • OBJECTIVES: To examine whether a lower hematocrit was associated with a lower prostate-specific antigen (PSA), when stratifying by body mass index (BMI) in healthy men.
  • PSA test is widely used in screening for prostate cancer.
  • Many studies have found that PSA levels inversely correlate with BMI.
  • We obtained information on age, BMI, PSA, hematocrit, and smoking status.
  • RESULTS: In all subjects, older age and lower BMI were weakly correlated with a higher PSA (r = 0.20, P <.001 and r = -0.05, P <.001, respectively).
  • A multiple regression model for predicting PSA was constructed using age, current smoking status, and hematocrit for each BMI category.
  • After controlling for age and smoking, PSA increased significantly with increasing hematocrit in participants with BMIs of 18.5-30 kg/m(2) (all P <.001).
  • For example, in men with a BMI of 22-25 kg/m(2), slight increases (1.4% increase; 95% confidence interval, 1.0%-1.9%) were observed in PSA with a 1-unit increase in hematocrit.
  • CONCLUSIONS: In healthy men with a BMI of 18.5-30 kg/m(2), a lower hematocrit was significantly associated with a lower PSA.
  • Hemodilution may explain the lower PSA levels observed in men with a higher BMI, resulting in an inverse relationship between BMI and PSA.

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2010 Mar;75(3):652-3; author reply 653 [20211373.001]
  • (PMID = 19854477.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Tsuchiya N, Ohyama C, Habuchi T: [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)]. Gan To Kagaku Ryoho; 2005 Feb;32(2):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
  • Prostate specific antigen (PSA), which has high organ specificity, is an excellent tumor marker that has played a significant role in the diagnosis and treatment of prostate cancer.
  • Screening for prostate cancer using PSA is now widely employed in Japan, and increased detection of cases with organ-confined prostate cancer is hoped to result in a decreased number of cancer-specific deaths.
  • Although PSA has also played a critical role in as a marker for staging, assessment of treatment, and recurrence of prostate cancer, many useless biopsies are performed due to its low cancer specificity.
  • To increase the specificity in prostate cancer detection, PSA-related markers including PSAD (PSAPZD), PSAV, and age-specific PSA were advocated, and the ratio of free PSA to total PSA (% free PSA) is also used in a clinical setting.
  • However, since those markers can not satisfactorily exclude benign prostate diseases, various molecular forms of PSA have been analyzed using proteomics and glycomics.
  • Recently, it was demonstrated that plasma free PSA consisted of precursor PSA (pPSA) and other isoforms, suggesting that [-2] pPSA may be a helpful marker for prostate cancer.
  • Our group reported that a sugar chain structure of PSA in the serum of prostate cancer patients is different from that of patients with benign prostate hyperplasia.
  • The different sugar chain structure of PSA can be easily detected by a conventional method and is expected to be useful for differential diagnosis between malignant and benign prostate diseases.
  • [MeSH-major] Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Clinical Laboratory Techniques / trends. Diagnosis, Differential. Forecasting. Humans. Maackia / chemistry. Male. Neoplasm Staging. Plant Lectins. Protein Isoforms / blood. Sensitivity and Specificity


11. Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S: MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice. Reumatismo; 2009 Apr-Jun;61(2):132-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the time of the analysis (April 2009) the database included 3510 patients: 2469 (70.3%) with established RA, 675 (19.2%) with PsA and 366 (10.4%) with AS.
  • The cumulative follow up period was 8,787 patient-years (RA: 8,388, PsA: 157; AS: 242).
  • An interim analysis of efficacy was conducted on 2,148 RA patients.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Biological Products / therapeutic use. Immunosuppressive Agents / therapeutic use. Rheumatic Diseases / drug therapy. Rheumatology. Risk Assessment. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633800.001).
  • [ISSN] 0048-7449
  • [Journal-full-title] Reumatismo
  • [ISO-abbreviation] Reumatismo
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Biological Products; 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


12. Shadel WG, Fryer CS, Tharp-Taylor S: Uncovering the most effective active ingredients of antismoking public service announcements: the role of actor and message characteristics. Nicotine Tob Res; 2009 May;11(5):547-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: This study examined whether the appeal of actors (i.e., their likeability and attractiveness) used in antismoking public service announcements (PSAs) interacts with adolescents' risk of future smoking to predict adolescents' smoking resistance self-efficacy and whether the antismoking messages in the PSAs further moderate this relationship.
  • METHODS: We used a 2 (future smoking risk: low, high) x 2 (actor appeal: low, high) x 3 (PSA antismoking message: tobacco industry manipulation, short-term smoking effects, long-term smoking effects) study design.
  • A diverse sample of 110 adolescents (aged 11-17 years), with varying levels of experience with smoking, rated their smoking resistance self-efficacy after viewing each of the PSAs in each design cell.
  • RESULTS: Overall, PSAs that used long-term smoking effects messages were associated with the strongest smoking resistance self-efficacy, followed in turn by PSAs that used short-term smoking effects messages and by tobacco industry manipulation messages.
  • We found a significant interaction of actor appeal and PSA antismoking message.
  • The use of more appealing actors was associated with stronger smoking resistance self-efficacy only in long-term smoking effects PSAs.
  • The use of less appealing actors was associated with stronger smoking resistance self-efficacy for tobacco industry manipulation PSAs and short-term smoking effects PSAs.
  • DISCUSSION: Antismoking PSAs that emphasize long-term smoking effects are most strongly associated with increased smoking resistance self-efficacy.
  • The effect of these PSAs can be strengthened by using actors whom adolescents perceive to be appealing.

  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tob Control. 2000;9 Suppl 2:II18-31 [10841588.001]
  • [Cites] Addiction. 2001 Feb;96(2):313-23 [11182877.001]
  • [Cites] Tob Control. 2002 Jun;11 Suppl 2:ii43-6 [12034981.001]
  • [Cites] Am J Public Health. 2002 Jun;92(6):901-7 [12036775.001]
  • [Cites] J Health Commun. 2002 Mar-Apr;7(2):123-37 [12049421.001]
  • [Cites] Nicotine Tob Res. 2002 Aug;4(3):321-32 [12215241.001]
  • [Cites] J Health Commun. 2003 May-Jun;8(3):229-47 [12857653.001]
  • [Cites] Am J Public Health. 2004 Feb;94(2):255-7 [14759936.001]
  • [Cites] Tob Control. 2004 Sep;13(3):283-8 [15333885.001]
  • [Cites] J Health Commun. 2004 May-Jun;9(3):259-74 [15360037.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Sep 4;36 Suppl 4:11S-16S [3116391.001]
  • [Cites] Health Psychol. 1992;11(6):377-85 [1286657.001]
  • [Cites] JAMA. 1998 Mar 11;279(10):772-7 [9508154.001]
  • [Cites] Am J Public Health. 2006 May;96(5):906-13 [16571709.001]
  • [Cites] J Health Commun. 2008 Jul-Aug;13(5):480-500 [18661389.001]
  • [Cites] Health Psychol. 2008 May;27(3 Suppl):S224-32 [18979975.001]
  • [Cites] Health Educ Res. 2009 Feb;24(1):42-8 [18203679.001]
  • (PMID = 19372574.001).
  • [ISSN] 1469-994X
  • [Journal-full-title] Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • [ISO-abbreviation] Nicotine Tob. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA148789; United States / NIDA NIH HHS / DA / R21 DA019920; United States / NIMHD NIH HHS / MD / 2P60MD00207-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2671467
  •  go-up   go-down


13. Inoue T, Maeno A, Talbot C Jr, Zeng Y, Yeater DB, Leman ES, Kulkarni P, Ogawa O, Getzenberg RH: Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells. Prostate; 2009 Jun 1;69(8):861-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a 5.3-kb region of the PSA promoter containing androgen response elements, the participation of PURalpha in androgen regulated gene expression was determined.
  • Most strikingly, ectopic expression of PURalpha induced transcriptional activity of the 5.3-kb PSA promoter containing androgen response elements, without androgen stimulation.
  • [MeSH-minor] Animals. Antibodies. Base Sequence. Cell Differentiation. Cell Line, Tumor. Genetic Vectors. Humans. Male. Mice. Mice, Nude. Retroviridae / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcriptional Activation. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19267365.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE14464
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / DNA-Binding Proteins; 0 / PURA protein, human; 0 / Transcription Factors
  •  go-up   go-down


1
Advertisement
4. Aliaev IuG, Krupinov GE, Bezrukov EA, Grigorian VA, Amosov AV, Chalyĭ ME, Kobzev DN, Bruk IuF, Shestiperov PA: [Treatment of prostatic cancer with high intensity focused ultrasound (HIFU) using Ablatherm device]. Urologiia; 2007 Nov-Dec;(6):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follow-up PSA measurements and control sextant biopsies were made.
  • The median PSA nadir 1.5-3.0 months after treatment ranged from 0.10 ng/ml (in low-risk localized prostate cancer group) to 2.50 ng/ml (in patients with disseminated process).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649659.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


15. Kehinde EO, Maghrebi MA, Anim JT: The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol; 2008 Apr;15(2):3967-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
  • The use of prostate specific antigen (PSA) in screening for PCa may detect even indolent disease for which radical prostatectomy may not be necessary.
  • Currently available criteria such as histological grade, PSA level, stage of the disease do not always predict outcome.
  • This paper is a review of studies using these novel markers in order to determine whether prostate cancer patients with the following characteristics have more aggressive cancer than those without: a) high serum levels of cathepsin B, survivin, Her - 2 / neu, IGFBP-2;.
  • b) low serum stefin A, IGFBP-3, c) positive immuno-staining of primary tumors for Her-2/neu, survivin and cathepsin B / stefin A ratio > 1 and d) gene expression of AMACR, HER-2/neu, high Bcl-2: Bax ratio and EZH2 in cancer cells.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology
  • [MeSH-minor] Cathepsin B / blood. Cathepsin B / metabolism. Cystatin B. Cystatins / blood. Cystatins / metabolism. Cysteine Proteinase Inhibitors / blood. Cysteine Proteinase Inhibitors / metabolism. Disease Progression. Humans. Inhibitor of Apoptosis Proteins. Insulin-Like Growth Factor Binding Proteins / genetics. Insulin-Like Growth Factor Binding Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Predictive Value of Tests. Prognosis. Receptor, Epidermal Growth Factor / blood. Receptor, Epidermal Growth Factor / metabolism


16. Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M 3rd, Hsu IC: Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):1106-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirteen patients have achieved a PSA nadir < or =0.1 ng/ml, but at the time of writing this endpoint has not yet been reached for all patients.
  • All patients are alive; however 2 have experienced biochemical failure, both with PSA nadirs > or =1, and have subsequently been found to have distant metastases.
  • [MeSH-major] Brachytherapy / methods. Neoplasm Recurrence, Local / radiotherapy. Prostatic Neoplasms / radiotherapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197119.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


17. Wu X, Chen VW, Andrews PA, Chen L, Ahmed MN, Schmidit B, Hsieh M, Fontham ET: Initial treatment patterns for clinically localized prostate cancer and factors associated with the treatment in Louisiana. J La State Med Soc; 2005 Jul-Aug;157(4):188-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed the associations of initial treatment with demographic factors such as age, race, health insurance status, type of healthcare facility, area of residence, county poverty, and clinical factors such as Gleason score, PSA, and comorbidity in univariate and logistic multivariate regression analyses.
  • Poverty level and comorbidity were inversely associated with receiving aggressive therapy in univariate analysis.
  • Patients with elevated PSA and high Gleason scores were less likely to receive radical prostatectomy even after the adjustment.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16250368.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Grant] United States / ODCDC CDC HHS / CC / US5/CCU621886
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Ojea Calvo A, Pérez Rodríguez A, Domínguez Freire F, Alonso Rodrigo A, Rodríguez Iglesias B, Benavente Delgado J, Barros Rodríguez JM, González Piñeiro A, Otero García M, Muñoz Garzón V: [Local recurrence after radical prostatectomy and salvage radiotherapy]. Arch Esp Urol; 2005 Jan-Feb;58(1):17-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Recidiva local después de la prostatectomía radical y radioterapia de rescate.
  • We detected biochemical recurrence (PSA > 0.20 ng/ml) in 75 (26%) patients.
  • 75 patients with biochemical recurrence, 9 (12%) were diagnosed of local recurrence by the following criteria: a) First PSA obtained 6 weeks after radical prostatectomy < 0.20 ng/ml.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Prostatectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801646.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


19. Sengupta S, Horowitz PM, Karsten SL, Jackson GR, Geschwind DH, Fu Y, Berry RW, Binder LI: Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry; 2006 Dec 19;45(50):15111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro.
  • A recent genetic screen identified puromycin-sensitive aminopeptidase (PSA) as a potent modifier of tau-induced pathology and suggested PSA as a possible tau-degrading enzyme.
  • Here we have extended these observations using human recombinant PSA purified from Escherichia coli.
  • The enzymatic activity and characteristics of the purified PSA were verified using chromogenic substrates, metal ions, and several specific and nonspecific protease inhibitors, including puromycin.
  • PSA was shown to digest recombinant human full-length tau in vitro, and this activity was hindered by puromycin.
  • Additionally, PSA was able to digest soluble tau purified from normal human brain to a greater extent than either soluble or PHF tau purified from AD brain, indicating that post-translational modifications and/or polymerization of tau may affect its digestion by PSA.
  • These results are consistent with observations that PSA modulates tau levels in vivo and suggest that this enzyme may be involved in tau degradation in human brain.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17154549.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG021661; United States / NIA NIH HHS / AG / AG016570; United States / NINDS NIH HHS / NS / NS49760; United States / NINDS NIH HHS / NS / NS046489; United States / NIGMS NIH HHS / GM / T32 GM008152; United States / NIA NIH HHS / AG / AG14453
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / tau Proteins; 4A6ZS6Q2CL / Puromycin; EC 3.4.11.- / Aminopeptidases; EC 3.4.11.14 / enkephalin degrading enzyme
  •  go-up   go-down


20. Patel H, Mick R, Finlay J, Zhu TC, Rickter E, Cengel KA, Malkowicz SB, Hahn SM, Busch TM: Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res; 2008 Aug 1;14(15):4869-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The time course of serum prostate-specific antigen (PSA) response to photodynamic therapy (PDT) of prostate cancer was measured.
  • Serum PSA level was measured within 2 months before PDT (baseline), and at day 1; weeks 1 to 3; months 1, 2, and 3; months 4 to 6; and months 7 to 11 after PDT.
  • RESULTS: At 24 hours after PDT, serum PSA increased by 98% +/- 36% (mean +/- SE) relative to baseline levels (P = 0.007).
  • When patients were dichotomized based on median PDT dose, those who received high PDT dose showed a 119% +/- 52% increase in PSA compared with a 54% +/- 27% increase in patients treated at low PDT dose.
  • Patients treated with high versus low PDT dose showed a median biochemical delay of 82 versus 43 days (P = 0.024), with biochemical delay defined as the length of time between PDT and a nonreversible increase in PSA to a value greater than or equal to baseline.
  • CONCLUSIONS: Results show PDT to induce large, transient increases in serum PSA levels.
  • Patients who experienced high PDT dose showed greater short-term increase in PSA and a significantly more durable PSA response (biochemical delay).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1997 May;157(5):1744-7 [9112518.001]
  • [Cites] Photochem Photobiol. 1995 Nov;62(5):882-6 [8570727.001]
  • [Cites] Photochem Photobiol. 1998 Jan;67(1):140-9 [9477772.001]
  • [Cites] Eur Urol. 1998 Sep;34(3):193-7 [9732191.001]
  • [Cites] BJU Int. 1999 May;83(7):783-5 [10368196.001]
  • [Cites] Photochem Photobiol. 2005 Jan-Feb;81(1):96-105 [15535736.001]
  • [Cites] Urol Oncol. 2005 Jan-Feb;23(1):8-11 [15885576.001]
  • [Cites] J Photochem Photobiol B. 2005 Jun 1;79(3):211-22 [15896648.001]
  • [Cites] J Photochem Photobiol B. 2005 Jun 1;79(3):231-41 [15896650.001]
  • [Cites] BJU Int. 2005 Oct;96(6):754-8 [16153193.001]
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8198-203 [16278473.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Urol. 2006 Apr;175(4):1201-7 [16515960.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):356-63 [16392142.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):427-34 [16788929.001]
  • [Cites] Int J Urol. 2006 Jul;13(7):947-50 [16882060.001]
  • [Cites] J Vasc Interv Radiol. 2006 Sep;17(9):1441-8 [16990463.001]
  • [Cites] J Biomed Opt. 2007 Jan-Feb;12(1):014022 [17343497.001]
  • [Cites] Photochem Photobiol. 2006 Nov-Dec;82(6):1638-44 [16879035.001]
  • [Cites] Photochem Photobiol. 2006 Sep-Oct;82(5):1270-8 [16808592.001]
  • [Cites] Radiology. 2007 Jul;244(1):196-204 [17507719.001]
  • [Cites] Photochem Photobiol. 2007 May-Jun;83(3):738-48 [17576383.001]
  • [Cites] J Urol. 2007 Nov;178(5):1974-9; discussion 1979 [17869307.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):651-60 [11297261.001]
  • [Cites] Photochem Photobiol. 2002 Apr;75(4):398-405 [12003130.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1427-32 [12352410.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1327-31 [14502284.001]
  • [Cites] Photochem Photobiol. 2003 Sep;78(3):271-7 [14556314.001]
  • [Cites] Neoplasia. 2004 May-Jun;6(3):224-33 [15153334.001]
  • [Cites] J Urol. 1994 May;151(5):1411-5 [8158797.001]
  • [Cites] Clin Biochem. 1995 Jun;28(3):221-41 [7554241.001]
  • [Cites] Urol Clin North Am. 1997 May;24(2):293-7 [9126226.001]
  • (PMID = 18676760.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-109456; United States / NCI NIH HHS / CA / CA087971-05; United States / NCI NIH HHS / CA / R01 CA109456; United States / NCI NIH HHS / CA / P01 CA-87971; United States / NCI NIH HHS / CA / R01 CA085831-06A2; United States / NCI NIH HHS / CA / R01 CA085831; United States / NCI NIH HHS / CA / P01 CA087971-05; United States / NCI NIH HHS / CA / R01 CA-85831; United States / NCI NIH HHS / CA / R01 CA109456-04; United States / NCI NIH HHS / CA / P01 CA087971
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0A85BJ22L6 / motexafin lutetium; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS110065; NLM/ PMC2680073
  •  go-up   go-down


21. Castelino M, Barton A: Genetic susceptibility factors for psoriatic arthritis. Curr Opin Rheumatol; 2010 Mar;22(2):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Psoriatic arthritis (PsA) has a large genetic component to its heritability, yet investigation into the genetic basis of the disease has lagged behind other rheumatic diseases mainly because of the difficulty in defining classification criteria that would accurately differentiate it from other forms of inflammatory arthritis.
  • However, using a variety of approaches, some confirmed associations have now been identified with PsA susceptibility, making a review of these recent developments timely.
  • RECENT FINDINGS: Family studies continue to suggest a large genetic contribution to PsA.
  • Using a candidate gene approach, genes robustly confirmed to be associated with psoriasis vulgaris (PsV) have also been found to be associated with PsA (HLA-Cw*0602, IL23R, IL12B).
  • There is less overlap reported with rheumatoid arthritis (RA) than PsV susceptibility loci but one report suggests that the AFF3 locus may be associated with both RA and PsA.
  • The bulk of evidence so far suggests that the genetic factors underlying PsV are also associated with PsA suggesting that future studies of PsV could include patients with PsA.


22. Liu M, Hashi Y, Song Y, Lin JM: Simultaneous determination of carbamate and organophosphorus pesticides in fruits and vegetables by liquid chromatography-mass spectrometry. J Chromatogr A; 2005 Dec 2;1097(1-2):183-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Samples were extracted with acetonitrile; and then prepared by dispersive solid-phase extraction (dispersive-SPE) with primary secondary amine (PSA) as the sorbent.
  • [MeSH-major] Carbamates / analysis. Chromatography, Liquid / methods. Fruit. Mass Spectrometry / methods. Organophosphorus Compounds / analysis. Vegetables
  • [MeSH-minor] Food Contamination / analysis. Pesticides / analysis. Reproducibility of Results

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257002.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carbamates; 0 / Organophosphorus Compounds; 0 / Pesticides
  •  go-up   go-down


23. Bantis A, Patsouris E, Gonidi M, Kavantzas N, Tsipis A, Athanassiadou AM, Aggelonidou E, Athanassiadou P: Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas. Tumori; 2009 Nov-Dec;95(6):744-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results were correlated with pathological stage, Gleason score and serum PSA.
  • The multiple linear regression model showed a statistically significance increase in telomerase RNA expression with increased Gleason score (P < 0.0001) and preoperative serum PSA values (P = 0.0125).
  • DNA ploidy status also varied significantly with Gleason score (P < 0.0001) and preoperative serum PSA values (P = 0.0110).
  • [MeSH-major] DNA, Neoplasm. Ploidies. Prostate-Specific Antigen / blood. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Telomerase / metabolism


24. Zhang Y, Schnoes AM, Clapp AR: Dithiocarbamates as capping ligands for water-soluble quantum dots. ACS Appl Mater Interfaces; 2010 Nov;2(11):3384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A biphasic exchange procedure efficiently replaces the existing hydrophobic capping ligands on the QD surface with the newly formed DTCs.
  • The mean density of DTC-ligands per nanocrystal was estimated through a mass balance calculation which suggested nearly complete coverage of the available nanocrystal surface.
  • The accessibility of the QD surface was evaluated by self-assembly of His-tagged dye-labeled proteins and peptides using fluorescence resonance energy transfer.
  • In general, DTC-capped CdSe-ZnS QDs have many advantages over other water-soluble QD formulations and provide a flexible chemistry for controlling the QD surface functionalization.

  • Hazardous Substances Data Bank. Water .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053924.001).
  • [ISSN] 1944-8244
  • [Journal-full-title] ACS applied materials & interfaces
  • [ISO-abbreviation] ACS Appl Mater Interfaces
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Thiocarbamates; 059QF0KO0R / Water
  •  go-up   go-down


25. Albensi BC, Toupin JD, Oikawa K, Oliver DR: Controlled pulse delivery of electrical stimulation differentially reduces epileptiform activity in Mg2+-free-treated hippocampal slices. Brain Res; 2008 Aug 21;1226:163-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the higher frequency protocol, 50 Hz was similarly effective at significantly (p < 0.05) suppressing several aspects of epileptiform activity (but not for reduction of population-spike amplitude).

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Brain Res. 2008 Dec 9;1244:173
  • (PMID = 18582443.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Guo Q, Minami N, Mori N, Nagasaka M, Ito O, Kurosawa H, Kanazawa M, Kohzuki M: Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats. Hypertens Res; 2008 Mar;31(3):525-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At age 18 weeks, IS and sympathetic activity were evaluated by an euglycemic hyperinsulinemic glucose clamp technique and power spectral analysis of systolic blood pressure, respectively.
  • Aze, Olm, or Exe significantly increased the capillary density and percentage of insulin-sensitive type I fiber.
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Combined Modality Therapy. Disease Models, Animal. Drug Therapy, Combination. Heart Rate / drug effects. Insulin / physiology. Male. Muscle, Skeletal / blood supply. Muscle, Skeletal / drug effects. Muscle, Skeletal / pathology. Rats. Rats, Inbred SHR. Regression Analysis. Sympathetic Nervous System / drug effects. Sympathetic Nervous System / physiopathology

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497473.001).
  • [ISSN] 0916-9636
  • [Journal-full-title] Hypertension research : official journal of the Japanese Society of Hypertension
  • [ISO-abbreviation] Hypertens. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Dihydropyridines; 0 / Imidazoles; 0 / Insulin; 0 / Tetrazoles; 2517-04-6 / Azetidinecarboxylic Acid; 8W1IQP3U10 / olmesartan; PV23P19YUG / azelnidipine
  •  go-up   go-down


27. Zhang S, Du P, Li F: Detection of prostate specific antigen with 3,4-diaminobenzoic acid (DBA)-H(2)O(2)-HRP voltammetric enzyme-linked immunoassay system. Talanta; 2007 Jun 15;72(4):1487-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new voltammetric enzyme-linked immunoassay system of 3,4-diaminobenzoic acid (DBA)-H(2)O(2)-horseradish peroxidase (HRP) for sensitive detection of prostate specific antigen (PSA) in human serum was present.
  • In the proposed procedure, labelled HRP efficiently catalyzed the oxidation reaction of DBA by H(2)O(2) and generated the electroactive product, 2,2'-biamino-4,4'-bicarboxyl azobiphenyl, which produced a sensitive second-order derivative linear sweep voltammetric peak at potential of -0.62V (versus SCE) in Britton-Robinson (BR) buffer solution.
  • The proposed new system could be used for detection of PSA ranging from 0.20 to 16.0ngml(-1) with a detection limit of 0.10ngml(-1), which was five times lower than that of the traditional o-phenylendiamine spectrophotometric enzyme-linked immunosorbent assay (ELISA) method.
  • The proposed electrochemical ELISA method is simple, inexpensive, reproducible and sensitive, which shows potential for detecting PSA in clinical diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19071788.001).
  • [ISSN] 1873-3573
  • [Journal-full-title] Talanta
  • [ISO-abbreviation] Talanta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W: Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol; 2005 Aug;174(2):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: There is no current standard treatment for patients with prostate cancer who have received hormonal therapy but have an increasing prostate specific antigen (PSA) without radiographic evidence of metastasis.
  • The vaccine consisted of recombinant vaccinia viruses containing the PSA and B7.1 costimulatory genes as prime vaccinations, and avipox-PSA as boosters.
  • After 6 months patients with an increasing PSA and no metastasis may receive a combination of both treatments.
  • In the vaccine arm median time to treatment failure was 9.9 months with 13 of 21 decreases in PSA velocity vs 7.6 months with 16 of 21 decreases in PSA velocity in the nilutamide arm (p =0.28).
  • Of the patients in the nilutamide arm 8 had vaccine added at the time of PSA progression.
  • Of the patients in the vaccine arm 12 had nilutamide added at the time of PSA progression.
  • CONCLUSIONS: Further studies are merited to investigate the role of combining vaccine with antiandrogen therapy or vaccine followed by vaccine plus antiandrogen therapy in this patient population.


29. Stock RG, Klein TJ, Cesaretti JA, Stone NN: Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys; 2009 Jul 1;74(3):753-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
  • These patients were free of biochemical failure (American Society for Therapeutic Radiology and Oncology [ASTRO] definition) during the first 5 post-treatment years and had a documented 5-year prostate-specific antigen (PSA) value.
  • RESULTS: The actuarial 10-year freedom from PSA failure rate was 97% using the ASTRO definition and 95% using the Phoenix definition.
  • The median 5-year PSA level was 0.03 ng/mL (range, 0-3.6).
  • The 5-year PSA value was <or=0.01 in 47.7%, >0.01-0.10 in 31.1%, >0.10-0.2 in 10.2%, >0.2-0.5 in 7.82%, and >0.5 in 3.10%.
  • The 5-year PSA value had prognostic significance, with a PSA value of <or=0.2 ng/mL (n = 661) corresponding to a 10-year freedom from PSA failure rate of 99% with the ASTRO definition and 98% with the Phoenix definition vs. 86% (ASTRO definition) and 81% (Phoenix definition) for a PSA value >or=0.2 ng/mL (n = 81; p < .0001).
  • The 5-year PSA value is prognostic, and patients with a PSA value <0.2 ng/mL are unlikely to develop subsequent biochemical relapse.
  • [MeSH-major] Neoplasm Recurrence, Local / diagnosis. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis


30. Diallo JS, Aldejmah A, Mouhim AF, Péant B, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM, Saad F: NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res; 2007 Dec 1;13(23):7044-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Normal, prostatic intraepithelial neoplasia (PIN), hormone-sensitive (HS) PCa, and hormone-refractory (HR) PCa tissues were used to build tissue microarrays encompassing a total of 135 patients.
  • Interestingly, the top-ranking RPART model generated [IBS = 0.107; 95% confidence interval (95% CI), 0.065-0.128] included surgical margin status and NOXA and PUMA expression, although recurrent prognostic classification schemes obtained in the top 10 models favored a survival tree model containing margin status, NOXA expression, and preoperative prostate-specific antigen (PSA) (IBS = 0.114; 95% CI, 0.069-0.142).
  • CONCLUSION: We conclude that NOXA and PUMA expression may be linked to PCa progression and propose further validation of a survival tree model including surgical margin status, NOXA expression, and preoperative PSA for predicting BCR.
  • [MeSH-major] Apoptosis Regulatory Proteins / biosynthesis. Biomarkers, Tumor / biosynthesis. Neoplasm Recurrence, Local / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis / genetics. Apoptosis / physiology. Cell Line, Tumor. Disease Progression. Humans. Kaplan-Meier Estimate. Male. Microarray Analysis. Middle Aged

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056181.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BBC3 protein, human; 0 / Biomarkers, Tumor; 0 / PMAIP1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


31. Enger SM, Van den Eeden SK, Sternfeld B, Loo RK, Quesenberry CP Jr, Rowell S, Sadler MC, Schaffer DM, Habel LA, Caan BJ: California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health; 2006;6:172
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PSA testing rates (75% overall) were highest among black participants.
  • The sensitivity and specificity can be assessed by comparing self-reported data, such as PSA testing, diabetes, and history of cancer, to health plan data.
  • The California Men's Health Study and other cohorts nested within comprehensive health delivery systems can make important contributions in the area of men's health.

  • MedlinePlus Health Information. consumer health - Healthy Aging.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):887-92 [10548317.001]
  • [Cites] J Am Med Womens Assoc. 1995 Mar-Apr;50(2):40-4 [7722205.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Nov;24(11):1475-87 [11126345.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6828-31 [2819722.001]
  • [Cites] JAMA. 1996 Jun 5;275(21):1646-50 [8637137.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):764-8 [8824546.001]
  • [Cites] Am J Epidemiol. 1997 Nov 15;146(10):856-69 [9384206.001]
  • [Cites] Epidemiol Rev. 1998;20(1):1-14 [9762505.001]
  • [Cites] Epidemiol Rev. 1998;20(1):57-70 [9762509.001]
  • [Cites] J Am Diet Assoc. 1998 Nov;98(11):1290-6 [9813585.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5117-22 [9823321.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1225-30 [10096552.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):178-87 [10192650.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1123-31 [16236996.001]
  • [Cites] Cancer Causes Control. 2002 Jun;13(5):407-15 [12146845.001]
  • [Cites] Circulation. 2003 Aug 19;108(7):802-7 [12900344.001]
  • [Cites] Am J Epidemiol. 2004 Jan 1;159(1):83-93 [14693663.001]
  • [Cites] Public Health Rep. 2004 Jul-Aug;119(4):388-95 [15219795.001]
  • [Cites] Am J Epidemiol. 1977 Sep;106(3):184-7 [900117.001]
  • [Cites] Epidemiology. 1990 Sep;1(5):405-8 [2078618.001]
  • [Cites] Am J Epidemiol. 1991 Jun 15;133(12):1231-45 [2063831.001]
  • [Cites] J Urol. 1992 Nov;148(5):1549-57; discussion 1564 [1279218.001]
  • [Cites] Med Sci Sports Exerc. 1993 Jan;25(1):81-91 [8423759.001]
  • [Cites] Am J Epidemiol. 1993 Nov 1;138(9):723-34 [8237987.001]
  • [Cites] Stroke. 1994 Oct;25(10):1924-30 [8091435.001]
  • [Cites] Int J Impot Res. 2000 Aug;12(4):197-204 [11079360.001]
  • (PMID = 16813653.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC1569841
  •  go-up   go-down


32. Nichol AM, Warde P, Bristow RG: Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer; 2005 Sep 1;104(5):891-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, the intermediate-risk prostate carcinoma grouping is defined on the basis of prostate-specific antigen (PSA), tumor classification (T classification), and Gleason score.
  • Emerging evidence suggests that additional prognostic information may be derived from the percentage of positive core needle biopsies at the time of diagnosis and/or from the pretreatment PSA doubling time.
  • Patients in the intermediate-risk group should be entered into well designed, randomized clinical trials of dose-escalated EBRT and AD with sufficient power to address biochemical failure and cause-specific survival endpoints.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007687.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 154
  •  go-up   go-down


33. Deck J, Bibevski S, Gnecchi-Ruscone T, Bellina V, Montano N, Dunlap ME: Alpha7-nicotinic acetylcholine receptor subunit is not required for parasympathetic control of the heart in the mouse. Physiol Genomics; 2005 Jun 16;22(1):86-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spectral analysis of heart rate variability [power spectral analysis (PSA)] was performed for the evaluation of resting autonomic tone to the heart.
  • PSA curves were similar between normal, wild-type, and Chrna7 mice.

  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ATROPINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797970.001).
  • [ISSN] 1531-2267
  • [Journal-full-title] Physiological genomics
  • [ISO-abbreviation] Physiol. Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chrna7 protein, mouse; 0 / Receptors, Nicotinic; 0 / alpha7 Nicotinic Acetylcholine Receptor; 3C9PSP36Z2 / Hexamethonium; 7C0697DR9I / Atropine; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


34. Ashley T: Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer. J Insur Med; 2005;37(4):261-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer.
  • The Prostate Cancer Prevention Trial yields a means to evaluate PSA screening for prostate cancer detection.
  • The receiver operating characteristic curve shows that PSA above 2.5 provides optimum sensitivity and specificity for prostate cancer diagnosis by needle biopsy.
  • However, the maximum positive predictive value of 48% occurs at PSA above 4.0 and does not increase at higher PSA cutpoints.
  • [MeSH-major] Prostate-Specific Antigen / analysis. Prostatic Neoplasms / diagnosis. Sensitivity and Specificity


35. Teeter AE, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ: Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int; 2009 Dec;104(11):1604-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
  • OBJECTIVE: To determine if prostate-specific antigen doubling time (PSADT), calculated from the first detectable PSA level after radical prostatectomy (RP) to the first PSA level of >or=0.2 ng/mL (early PSADT or ePSADT), correlated with 'standard' PSADT (henceforth PSADT) calculated using values >or=0.2 ng/mL, as a short PSADT following biochemical recurrence (BCR) after RP portends a poor prognosis and poor response to salvage treatment but this is based upon PSADT calculated using PSA values of >or=0.2 ng/mL.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Prostate-Specific Antigen / metabolism. Prostatectomy / methods. Prostatic Neoplasms / pathology. Salvage Therapy / methods


36. Brahmbhatt JV, Liou LS: Giant organ confined prostatic adenocarcinoma: a case report. J Med Case Rep; 2008;2:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE PRESENTATION: We describe a case of an otherwise healthy 71-year-old African male who presented with a PSA of 5800 ng/ml and a prostate volume of over 1000cc.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Aug;58(2 Suppl 1):71-7 [11502453.001]
  • [Cites] BJU Int. 2004 Apr;93(6):710-4 [15049977.001]
  • [Cites] Int J Urol. 2004 May;11(5):295-303 [15147545.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1625-30 [15747374.001]
  • [Cites] J Urol. 1993 Mar;149(3):510-5 [7679754.001]
  • [Cites] J Urol. 1991 Feb;145(2):313-8 [1703240.001]
  • [Cites] Hinyokika Kiyo. 2007 Feb;53(2):133-5 [17352166.001]
  • [Cites] Hinyokika Kiyo. 1995 Sep;41(9):683-5 [7484533.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • (PMID = 18226267.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2254427
  •  go-up   go-down


37. Bonkhoff H: [Prognostic factors in prostate cancer]. Pathologe; 2005 Nov;26(6):433-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to the PSA value, pathologic stage, as defined by the TNM system, Gleason grade and the surgical margin status, other markers have prognostic implications.
  • This includes the percent pattern 4/5 cancer, tumor volume, intraductal spread, large volume perineural invasion and molecular markers.
  • [MeSH-minor] Biomarkers, Tumor / blood. Cell Transformation, Neoplastic / pathology. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Precancerous Conditions / pathology. Prognosis. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Hyperplasia / pathology


38. Peterson JL, Buskirk SJ, Heckman MG, Crook JE, Ko SJ, Wehle MJ, Igel TC, Prussak KA, Pisansky TM: Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol; 2009 Nov;93(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate late toxicity in patients who received salvage external beam radiotherapy (EBRT) for a detectable prostate-specific antigen (PSA) level after radical prostatectomy (RP).
  • METHODS: A cohort of 308 consecutive patients underwent salvage EBRT from July 1987 through June 2003 for a detectable PSA level after RP.
  • CONCLUSIONS: Salvage EBRT for a detectable PSA level after RP is the only curative treatment in this setting.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prostate-Specific Antigen / blood. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766337.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


39. Steurer J, Held U, Schmidt M, Gigerenzer G, Tag B, Bachmann LM: Legal concerns trigger prostate-specific antigen testing. J Eval Clin Pract; 2009 Apr;15(2):390-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using prostate-specific antigen (PSA) screening as an example, we surveyed Swiss physicians and assessed the extent to which liability fears influenced their recommendation for testing.
  • Seventy-five per cent of both groups recommend regular PSA screening to men older than age 50.
  • Yet only 56% of the general physicians and 53% of the internists believe that PSA measurement is an effective screening method.
  • [MeSH-major] Attitude of Health Personnel. Defensive Medicine / legislation & jurisprudence. Mass Screening / utilization. Prostate-Specific Antigen / analysis


40. Remko M, Swart M, Bickelhaupt FM: Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorg Med Chem; 2006 Mar 15;14(6):1715-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives.
  • The analysis of molecular descriptors defined by Lipinski has shown that most of the compounds studied obey 'rule of five'.
  • Therefore, in the early stages of the design of ligands acting on imidazoline binding sites, it is becoming more important to determine the pKa, lipophilicity, water solubility, polar surface area, absorption, and other physicochemical properties associated with a drug, before synthetic work is undertaken, with the aim of avoiding the synthesis of compounds that are predicted to have poor biopharmaceutical characteristics.
  • [MeSH-minor] Adsorption. Computer Simulation. Hydrogen-Ion Concentration. Solubility. Structure-Activity Relationship. Surface Properties

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263295.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Lipids; 0 / Solvents
  •  go-up   go-down


46. Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED: Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer; 2008 Sep;6(2):103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients were treated with ispinesib 18 mg/m2 every 21 days and assessed for prostate-specific antigen (PSA) and measurable disease response at regular intervals.
  • Kinesin spindle protein expression in archival tumors, population ispinesib pharmacokinetics, and pharmacodynamic assessments of circulating lymphocytes were included.
  • Median duration of PSA or clinical progression-free survival was 9 weeks.
  • Immunohistochemical analysis of archival tumor specimens did not demonstrate significant KSP expression in most of the prostate cancer cases studied.
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Drug Evaluation. Drug Resistance, Neoplasm. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / drug therapy. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824433.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46441
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / KIF11 protein, human; 0 / Quinazolines; 0 / Taxoids; BKT5F9C2NI / ispinesib; EC 3.4.21.77 / Prostate-Specific Antigen; EC 3.6.1.- / Kinesin
  •  go-up   go-down


47. Kiknavelidze KG, Chanturaia ZM, Silagava DD, Nikoleishvili DO, Tsintsadze OV, Managadze LG: [Is sextant biopsy a valid method in diagnosis of prostatic cancer?]. Urologiia; 2006 Jul-Aug;(4):32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is sextant biopsy a valid method in diagnosis of prostatic cancer?].
  • Biopsy was performed in 386 men because of elevated PSA and/or abnormality in digital rectal examinations (DRE).
  • Thus, our results show that laterally directed sextant biopsy is an effective method of PC detection among suspected patients (PSA > 4 ng/ml) with large volume prostates and abnormal findings at DRE.
  • [MeSH-major] Prostate / pathology. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058678.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


48. Werny DM, Saraiya M, Gregg EW: Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol; 2006 Nov 15;164(10):978-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have shown that diabetic men have a lower risk of prostate cancer and that this association may be related to time since diagnosis.
  • The authors examined the association between diabetes and prostate-specific antigen (PSA) levels, controlling for potential confounders, in a nationally representative cross-sectional survey of the US population (National Health and Nutrition Examination Survey 2001-2002).
  • Controlling for age, men with self-reported diabetes had a 21.6% lower geometric mean PSA level than men without diabetes.
  • The difference increased with years since diagnosis (>10 years: 27.5% lower geometric mean PSA level).
  • Overweight men who had had diabetes for more than 10 years had a predicted geometric mean PSA level 40.8% lower than that of nondiabetic, normal-weight men.
  • The mechanism of this association may involve the regulation of PSA by androgens, although the authors are unable to confirm this assertion.
  • Better understanding of the determinants of PSA level is needed to make the distinction between factors affecting the PSA test's accuracy and those altering the risk of prostate cancer.

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023544.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


49. Lim CH, Quinlan DM: Are doctors examining prostates in university hospital? Urology; 2007 Nov;70(5):843-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We have observed that serum prostate-specific antigen (PSA) testing is commonly performed for prostate assessment or screening but use of digital rectal examinations (DREs) appears inconsistent.
  • To better define suspected underperformance of DRE, we studied the frequency of combining DRE with PSA testing in prostate assessment.
  • Documentation of DREs and PSA testing, reasons for the urologist consultation, and the teams responsible for the patient's hospital care were assessed by a single chart reviewer familiar with the setting and format of the hospital medical records.
  • RESULTS: A total of 89 patients (45.18%) had PSA test results, 50 (25.38%) had DRE findings, and 34 (17.26%) had both DRE findings and PSA test results documented in the hospital medical record during their admission before the urologist consultation.
  • More medical patients had had PSA testing than had surgical patients (48.06% versus 39.88%).
  • CONCLUSIONS: Prostate cancer assessment or screening by combining DRE with PSA testing is often not done by doctors in a teaching university hospital.
  • [MeSH-major] Digital Rectal Examination / utilization. Practice Patterns, Physicians'. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis. Urology / standards


50. Kim DJ, Lee NE, Park JS, Park IJ, Kim JG, Cho HJ: Organic electrochemical transistor based immunosensor for prostate specific antigen (PSA) detection using gold nanoparticles for signal amplification. Biosens Bioelectron; 2010 Jul 15;25(11):2477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organic electrochemical transistor based immunosensor for prostate specific antigen (PSA) detection using gold nanoparticles for signal amplification.
  • We demonstrated a highly sensitive organic electrochemical transistor (OECT) based immunosensor with a low detection limit for prostate specific antigen/alpha1-antichymotrypsin (PSA-ACT) complex.
  • The poly(styrenesulfonate) doped poly(3,4-ethylenedioxythiophene) (PEDOT:PSS) based OECT with secondary antibody conjugated gold nanoparticles (AuNPs) provided a detection limit of the PSA-ACT complex as low as 1pg/ml, as well as improved sensitivity and a dynamic range, due to the role of AuNPs in the signal amplification.
  • The sensor performances were particularly improved in the lower concentration range where the detection is clinically important for the preoperative diagnosis and screening of prostate cancer.
  • [MeSH-major] Biosensing Techniques / instrumentation. Conductometry / instrumentation. Gold / chemistry. Immunoassay / instrumentation. Nanoparticles / chemistry. Prostate-Specific Antigen / analysis. Transistors, Electronic
  • [MeSH-minor] Amplifiers, Electronic. Equipment Design. Equipment Failure Analysis. Organic Chemicals / chemistry. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20435461.001).
  • [ISSN] 1873-4235
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organic Chemicals; 7440-57-5 / Gold; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


51. Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M 3rd, Shinohara K: Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int; 2009 Sep;104(5):600-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcomes were time to biochemical relapse-free survival, using the Phoenix definition of a prostate-specific antigen (PSA) nadir +2 ng/mL, and cancer-specific survival.
  • RESULTS: In all, 37 patients had SPPI during this period; after applying inclusion and exclusion criteria, 24 remained for analysis.
  • At the time of salvage therapy, the median time to the diagnosis of local recurrence was 49 months, the median PSA level was 3.36 ng/mL, the median PSA doubling time was 20 months, and all patients were clinically re-staged at <or=T2 with negative transrectal ultrasonography and/or magnetic resonance spectroscopy.
  • The PSA level was higher than the levels before SPPI at 3 months in all three failures, but lower in all 21 patients considered relapse-free.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Neoplasm Recurrence, Local / radiotherapy. Prostatic Neoplasms / radiotherapy. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245439.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


52. Maroni PD, Crawford ED: Screening for prostate cancer in 2006: PSA in the 21st century. N C Med J; 2006 Mar-Apr;67(2):136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for prostate cancer in 2006: PSA in the 21st century.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752718.001).
  • [ISSN] 0029-2559
  • [Journal-full-title] North Carolina medical journal
  • [ISO-abbreviation] N C Med J
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 13
  •  go-up   go-down


53. Hori J, Okuyama M, Azumi M, Kato Y, Saga Y, Hashimoto H, Tokumitsu M, Kakizaki H: [Indication of repeat prostate biopsy for the diagnosis of prostate cancer]. Hinyokika Kiyo; 2006 Nov;52(11):835-8; discussion 838-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of repeat prostate biopsy for the diagnosis of prostate cancer].
  • We retrospectively analyzed our experience of repeat prostate biopsy to establish its indication for the diagnosis of prostate cancer.
  • We compared patients' age, number of cores obtained during repeat biopsy, digital rectal examination findings, total prostate volume, the time from the first to the last biopsy, total prostate specific antigen (PSA) value, free PSA/total PSA ratio, PSA density and PSA velocity between cancer-positive and cancer-negative groups.
  • A statistically significant difference was only noted in age and PSA density.
  • Persistently elevated total PSA and a higher PSA density in cases with a negative initial biopsy might be a good indication of repeat prostate biopsy for the diagnosis of prostate cancer.


54. Xiong GB, Yao WL, Wu FH: [Shenfu Qiangjing decoction improves non-inflammatory and non-liquefied semen in kidney-yang deficiency men]. Zhonghua Nan Ke Xue; 2009 Dec;15(12):1138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both groups were observed for sperm viability, sperm motility, serum testosterone, seminal plasma PSA and improvement of kidney-yang deficiency symptoms before and after the medication.
  • The levels of serum T and seminal plasma PSA also showed significant differences before and after the treatment in the SQD group (P < 0.01) and between the two groups after the medication (P < 0.05).
  • [MeSH-minor] Adult. Humans. Male. Semen Analysis. Sperm Motility. Young Adult

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180429.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


55. Stephan C, Cammann H, Deger S, Schrader M, Meyer HA, Miller K, Lein M, Jung K: Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology; 2009 Oct;74(4):873-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
  • OBJECTIVES: To show discriminative power between patients with prostate cancer (PCa) and those with "no evidence of malignancy" using "benign" prostate-specific antigen (bPSA) and the new automated Access benign prostatic hyperplasia-associated (BPHA) research assay within a percent free PSA (%fPSA)-based artificial neural network (ANN) model.
  • METHODS: The sera from 287 patients with PCa and 254 patients with no evidence of malignancy were measured using the BPHA, total PSA (tPSA), and fPSA assays with Access immunoassay technology, with a 0-10 ng/mL tPSA range.
  • Two ANN models with Bayesian regularization and leave-one-out validation using the 4 input parameters of tPSA, %fPSA, age, and prostate volume and 1 containing BPHA/tPSA were constructed and compared by receiver operating characteristic curve analysis.
  • RESULTS: The BPHA/tPSA-based ANN reached the significant greatest area under the receiver operating characteristic curve (AUC 0.81; P = .0004 and P = .0024) and best specificity (53.9% and 44.5%) compared with the ANN without BPHA/tPSA (AUC 0.77; specificity 50% and 40.6%) and %fPSA (AUC 0.77; specificity 40.9% and 27.2%) at 90% and 95% sensitivity, respectively.
  • [MeSH-major] Neural Networks (Computer). Prostate-Specific Antigen / blood. Prostatic Hyperplasia / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


56. Sauter ER, Ganz PA, Ehya H, Hewett JE, Schlatter L, Kliethermes B, Daly MB: Prospective multicenter trial to determine the feasibility of collection and predictive ability of breast fluid analysis in postmenopausal women receiving SERMs. Breast; 2007 Oct;16(5):489-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter trial to determine the feasibility of collection and predictive ability of breast fluid analysis in postmenopausal women receiving SERMs.
  • Three biomarkers, cytology, fluid volume, and prostate-specific antigen (PSA), were analyzed.
  • Median PSA increased from 37.5 to 112 ng/L after treatment.
  • In conclusion, after treatment with tamoxifen or raloxifene, changes in both NAF cytology and PSA were generally favorable, consistent with their expected antiproliferative effective effect on the breast.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Body Fluids / chemistry. Breast Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nipples / pathology. Selective Estrogen Receptor Modulators / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Postmenopause. Predictive Value of Tests. Prospective Studies. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482465.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Selective Estrogen Receptor Modulators
  •  go-up   go-down


57. Kirkpatrick JP, Anscher MS: Radiotherapy for locally recurrent prostate cancer. Clin Adv Hematol Oncol; 2005 Dec;3(12):933-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, there is much controversy over how to treat patients with a rising prostate-specific antigen (PSA), but without overt metastases, after radical prostatectomy.
  • A recent randomized controlled trial of adjuvant radiotherapy versus observation following radical prostatectomy shows a significantly higher freedom from recurrence for patients receiving adjuvant radiotherapy, which may help to resolve the question of whether or not to wait for a rise in the PSA before offering treatment.
  • For patients with biochemical recurrence after prostatectomy, part of the problem lies in the difficulty in determining whether a rise in the PSA is a sign of local recurrence or a harbinger of distant metastases.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Biomarkers, Tumor / blood. Neoplasm Recurrence, Local / radiotherapy. Prostate-Specific Antigen / blood. Prostatic Neoplasms / radiotherapy


58. Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, Silva C, Cruz F, Dinis P: Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol; 2009;9:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.
  • BACKGROUND: Botulinum Toxin Type-A (BoNT/A) intraprostatic injection can induce prostatic involution and improve LUTS and urinary flow in patients with Benign Prostatic Enlargement (BPE).
  • Prostate volume, total serum PSA, maximal flow rate (Qmax), residual volume (PVR) and IPSS-QoL scores were determined at 1, 3, 6, 12 and 18 months post-treatment.
  • Albeit non significant, serum PSA showed a 25% decrease from baseline to month 6.
  • [MeSH-major] Botulinum Toxins, Type A / administration & dosage. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Dec;58(6 Suppl 1):25-32; discussion 32 [11750246.001]
  • [Cites] Eur Urol. 2009 Jul;56(1):134-40 [18649990.001]
  • [Cites] Urology. 2003 Aug;62(2):259-64; discussion 264-5 [12893330.001]
  • [Cites] Prostate. 1998 Sep 15;37(1):44-50 [9721068.001]
  • [Cites] Urology. 2005 Apr;65(4):670-4 [15833506.001]
  • [Cites] Urology. 2005 Oct;66(4):775-9 [16230137.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119 [16465187.001]
  • [Cites] BMC Urol. 2006;6:12 [16620393.001]
  • [Cites] BJU Int. 2006 Nov;98(5):1033-7; discussion 1337 [16956361.001]
  • [Cites] Yonsei Med J. 2006 Oct 31;47(5):706-14 [17066515.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):582-9 [17386969.001]
  • [Cites] Neurourol Urodyn. 2007 Oct;26(6 Suppl):920-7 [17705161.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):153-9 [17825981.001]
  • [Cites] Eur Urol. 2008 Aug;54(2):326-34 [18160204.001]
  • [Cites] Eur Urol. 2008 Oct;54(4):765-75 [18571306.001]
  • [Cites] J Urol. 2008 Oct;180(4):1314-7; discussion 1317 [18707733.001]
  • [Cites] Urology. 2009 Jan;73(1):90-4 [18995889.001]
  • [Cites] Scand J Urol Nephrol. 2009;43(3):206-11 [19308807.001]
  • [Cites] Toxicon. 2009 Oct;54(5):668-74 [19470342.001]
  • [Cites] Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70 [11750255.001]
  • (PMID = 19682392.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Other-IDs] NLM/ PMC2734751
  •  go-up   go-down


59. Lo KL, Chan MC, Wong A, Hou SM, Ng CF: Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. Int Urol Nephrol; 2010 Mar;42(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia.
  • METHODS: The records of 248 patients who presented with a first episode of AUR secondary to benign prostatic hyperplasia (BPH) and who could void successfully after the initial TWOC following treatment with an AR blocker were reviewed during the period January 1998 to December 2001.
  • Multivariate analysis indicated that only a prostate size >50 ml and serum prostate specific antigen (PSA) level during AUR >10 ng/dl were significant predictors of subsequent requirement for surgical intervention after a successful TWOC.
  • By using appropriate selection criteria, such as a large prostate size (>50 ml) or high serum PSA level during AUR (>10 microg/l), patients who are at greater risk of TWOC failure can be identified, and earlier surgical intervention can be offered to them.


60. Bohrer M, Schröder P, Welzel G, Wertz H, Lohr F, Wenz F, Mai SK: Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT (B-mode acquisition and targeting system) for prostate cancer. Strahlenther Onkol; 2008 Dec;184(12):674-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute and late genito-urinary (GU) and rectal toxicity and PSA values were evaluated after 1.5, 3, 6, 9 and 12 months.
  • There was no significant difference in PSA reduction between the groups.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Phys Eng Sci Med. 1999 Jun;22(2):29-47 [10474974.001]
  • [Cites] Technol Cancer Res Treat. 2003 Apr;2(2):161-70 [12680798.001]
  • [Cites] Urology. 2005 Mar;65(3):504-8 [15780365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):436-47 [12738318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):719-25 [10098426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1225-33 [12873665.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):635-44 [14529767.001]
  • [Cites] Strahlenther Onkol. 2007 Nov;183(11):617-24 [17960337.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500 [9635694.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1079-86 [9719118.001]
  • [Cites] J Urol. 2001 Sep;166(3):876-81 [11490237.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):595-601 [15145181.001]
  • [Cites] Strahlenther Onkol. 2006 Sep;182(9):531-6 [16944375.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1130-8 [12128112.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Strahlenther Onkol. 2007 Apr;183(4):203-10 [17406802.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):575-80 [10701736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):265-78 [11316572.001]
  • [Cites] Urologe A. 2004 Jan;43(1):43-51 [14747927.001]
  • [Cites] Radiother Oncol. 1993 Nov;29(2):176-83 [8310143.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1124-9 [12128111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1218-24 [12873664.001]
  • [Cites] Phys Med Biol. 2007 Sep 21;52(18):5655-65 [17804887.001]
  • [Cites] World J Urol. 2003 Sep;21(4):200-8 [12961097.001]
  • [Cites] Urology. 2005 Sep;66(3):566-70 [16140079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):378-87 [16563658.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):501-10 [9635695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 [12128107.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):965-73 [15989996.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Strahlenther Onkol. 2006 Apr;182(4):240-6 [16622626.001]
  • [Cites] Radiother Oncol. 2003 Nov;69(2):215-22 [14643961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):678-87 [16751060.001]
  • (PMID = 19107349.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


61. van Oort IM, Kok DE, Kiemeney LA, Hulsbergen-van de Kaa CA, Witjes JA: A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant". Urol Oncol; 2009 Sep-Oct;27(5):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BCR was defined as 2 consecutive PSA levels >0.10 ng/ml.
  • RESULTS: In the total group, the median age at the time of surgery was 62.7 years (42.4-73.4) and the median preoperative PSA level was 8.0 ng/ml.
  • [MeSH-minor] Adult. Aged. Disease Progression. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625570.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


62. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate; 2005 Feb 1;62(2):140-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The prostate glands of 90 men with elevated prostate-specific antigen (PSA) were imaged by dynamic contrast-enhanced MRI (DCE-MRI) before transrectal ultrasound-guided 14-cores prostate biopsy.
  • RESULTS: The detection rate of Cap in 57 patients with PSA < 10.0 ng/ml was 36.8% as determined by the initial biopsy.
  • Otherwise, we recommend the definitive diagnosis of Cap by utilizing DCE-MRI alone.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neoplasm Staging / methods. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Early Diagnosis. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity


63. Hammond A, Bryan J, Hardy A: Effects of a modular behavioural arthritis education programme: a pragmatic parallel-group randomized controlled trial. Rheumatology (Oxford); 2008 Nov;47(11):1712-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: People with RA or PsA were randomized to a modular behavioural or standard information-focused education programme, both delivered by experienced rheumatology health professionals at one large district general hospital.
  • Using an intent-to-treat analysis outcomes were compared at 6 and 12 months with analysis of covariance.
  • CONCLUSION: Attending a modular behavioural education programme is effective for at least 1 yr in enabling people with RA and PsA to reduce pain, improve psychological status and self-manage their condition.


64. Han HY, Wang XH, Wang NL, Ling MT, Wong YC, Yao XS: Lignans isolated from Campylotropis hirtella (Franch.) Schindl. decreased prostate specific antigen and androgen receptor expression in LNCaP cells. J Agric Food Chem; 2008 Aug 27;56(16):6928-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accumulating epidemiological data suggest that Asian men have lower incidences of prostate cancer and benign prostate hyperplasia (BPH) compared with American and European populations and may have benefited from their higher intake of phytoestrogens in their diet.
  • Their IC50 values for inhibition of prostate specific antigen (PSA) secretion were 19, 45, 110, 128, 137, and 186 microM, respectively, from C1 to C6 in LNCaP cells.
  • Further study showed that C1-5 down-regulated cellular PSA expression and C1-4 also decreased androgen receptor (AR) expression in LNCaP cells.
  • [MeSH-major] Fabaceae / chemistry. Lignans / pharmacology. Prostate-Specific Antigen / analysis. Receptors, Androgen / analysis
  • [MeSH-minor] Cell Line, Tumor. Humans. Male. Plant Roots / chemistry. Prostatic Neoplasms


65. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y: Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. Int J Cancer; 2008 Jul 15;123(2):430-435
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis.
  • The case-fatality rate following a diagnosis of prostate cancer is higher for Black men compared to White men.
  • Similar results were seen for studies from the pre-PSA era and free-health care settings.
  • In conclusion, Black men had a poorer prognosis which was not fully explained by comorbidity, PSA screening, or access to free health care, although few studies measure these factors well.
  • [MeSH-major] African Americans / statistics & numerical data. European Continental Ancestry Group / statistics & numerical data. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / ethnology


66. Schultz M, Parzinger H, Posdnjakov DV, Chikisheva TA, Schmidt-Schultz TH: Oldest known case of metastasizing prostate carcinoma diagnosed in the skeleton of a 2,700-year-old Scythian king from Arzhan (Siberia, Russia). Int J Cancer; 2007 Dec 15;121(12):2591-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine whether a 2,700-year-old tumor can be reliably diagnosed using microscopic and proteomic techniques and whether such prostate carcinomas show the same morphological pattern at the micro-level as modern-day carcinomas, this case was investigated.
  • The diagnosis mainly rests on the results of the microscopic examination of the lesions and the positive evidence of PSA, which is an important marker for the diagnosis of prostate cancer.
  • Sensitive and reliable biochemical markers (PSA) are an important precondition to detect such tumors in recent and ancient materials.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / history. Blotting, Western. Electrophoresis, Polyacrylamide Gel. History, Ancient. Humans. Male. Microscopy, Electron, Scanning. Middle Aged. Prostate-Specific Antigen / analysis. Prostate-Specific Antigen / history. Proteomics / methods. Siberia

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17918181.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


67. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, van Venrooij WJ, Metzger AL, Genovese MC, Robinson WH: Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis; 2007 Jun;66(6):712-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines.
  • METHODS: Serum samples from 56 patients with a diagnosis of rheumatoid arthritis of <6 months' duration were tested.
  • Cytokine profiles were also determined in samples from patients with psoriatic arthritis (PsA) and ankylosing spondylitis (n = 21), and from healthy individuals (n = 19).
  • Data were analysed using Kruskal-Wallis test with Dunn's adjustment for multiple comparisons, linear correlation tests, significance analysis of microarrays (SAM) and hierarchical clustering software.
  • RESULTS: Distinct antibody profiles were associated with subgroups of patients who exhibited high serum levels of tumour necrosis factor (TNF)alpha, interleukin (IL)1beta, IL6, IL13, IL15 and granulocyte macrophage colony-stimulating factor.
  • Only IL8/CXCL8 concentrations were higher in patients with PsA/ankylosing spondylitis (p = 0.02).
  • Proteomic analysis of serum autoantibodies, cytokines and chemokines enables stratification of patients with early rheumatoid arthritis into molecular subgroups.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Apr;105(8):1043-4 [10772647.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):728-35 [16269423.001]
  • [Cites] J Immunol Methods. 2001 Aug 1;254(1-2):109-18 [11406157.001]
  • [Cites] Arthritis Res. 2001;3(5):293-8 [11549370.001]
  • [Cites] Rheumatology (Oxford). 2001 Sep;40(9):988-94 [11561108.001]
  • [Cites] Cytometry. 2001 Sep 1;45(1):27-36 [11598944.001]
  • [Cites] Arthritis Rheum. 2001 Oct;44(10):2218-20 [11665960.001]
  • [Cites] Nat Med. 2002 Mar;8(3):295-301 [11875502.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):37-45 [11905836.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5885-92 [12023393.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2685-93 [12193742.001]
  • [Cites] Arthritis Rheum. 2002 Sep;46(9):2320-9 [12355479.001]
  • [Cites] Nature. 2003 May 15;423(6937):356-61 [12748655.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jun;2(6):473-88 [12776222.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2374-83 [12928384.001]
  • [Cites] Nat Biotechnol. 2003 Sep;21(9):1033-9 [12910246.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1245-50 [14520364.001]
  • [Cites] Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S59-64 [14969052.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] J Exp Med. 1989 Sep 1;170(3):865-75 [2504878.001]
  • [Cites] Nature. 1996 Oct 31;383(6603):787-93 [8893001.001]
  • [Cites] Nat Med. 1997 Feb;3(2):189-95 [9018238.001]
  • [Cites] J Exp Med. 1997 Jul 7;186(1):131-7 [9207007.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):746-54 [9466968.001]
  • [Cites] Curr Biol. 1997 Nov 1;7(11):836-43 [9480044.001]
  • [Cites] Nat Med. 1998 Jun;4(6):643 [9623950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Jan;6(1):89-95 [9874670.001]
  • [Cites] Clin Chem. 1999 May;45(5):616-8 [10222346.001]
  • [Cites] J Immunol Methods. 1999 Jul 30;227(1-2):41-52 [10485253.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3663-7 [15529362.001]
  • [Cites] J Rheumatol. 2004 Dec;31(12):2336-46 [15570632.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12):3866-77 [15593223.001]
  • [Cites] Trends Immunol. 2005 May;26(5):268-74 [15866240.001]
  • [Cites] J Immunol Methods. 2005 May;300(1-2):124-35 [15896801.001]
  • [Cites] Arthritis Res Ther. 2005;7(4):R784-95 [15987480.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2645-55 [16142722.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):610-21 [16467548.001]
  • [Cites] Annu Rev Immunol. 2001;19:163-96 [11244034.001]
  • (PMID = 16901957.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR 043584; United States / NHLBI NIH HHS / HV / N01 HV028183; United States / NIAMS NIH HHS / AR / K08 AR002133; United States / NIAMS NIH HHS / AR / K08 AR 02133; United States / NIAMS NIH HHS / AR / P01 AR043584; United States / NHLBI NIH HHS / HV / N01 HV 28183
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Biomarkers; 0 / Chemokines; 0 / Cytokines; 0 / Inflammation Mediators; 29VT07BGDA / Citrulline
  • [Other-IDs] NLM/ PMC1954670
  •  go-up   go-down


68. Barluenga J, Fernández MA, Aznar F, Valdés C: Cascade alkenyl amination/Heck reaction promoted by a bifunctional palladium catalyst: a novel one-pot synthesis of indoles from o-haloanilines and alkenyl halides. Chemistry; 2005 Apr 8;11(8):2276-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cascade alkenyl amination/Heck reaction promoted by a bifunctional palladium catalyst: a novel one-pot synthesis of indoles from o-haloanilines and alkenyl halides.
  • A novel approach for the synthesis of the important indole ring is described.
  • Indoles are obtained from o-bromoanilines and alkenyl halides in a Pd-catalyzed cascade process that involves an alkenyl amination followed by an intramolecular Heck reaction.
  • The overall process represents the first example of the participation of alkenyl amination reactions in Pd-catalyzed cascade reactions.
  • Initially, the relative reactivity of aryl and alkenyl bromides and chlorides towards Pd-catalyzed amination was investigated.
  • Competition experiments were carried out in the presence of primary and secondary amines, and these revealed the reactivity order alkenyl bromides > aryl bromides > alkenyl chlorides > aryl chlorides, as well as very high chemoselectivity; the more reactive halide was always favored.
  • Thereafter, optimized reaction conditions for the sequential alkenyl amination/Heck cyclization to give indoles were investigated with the model reaction of o-bromoaniline with alpha-bromostyrene.
  • An extensive screening of ligands, bases, and reaction conditions revealed that the [Pd2(dba)3]/DavePhos, NaOtBu, toluene combination at 100 degrees C were the optimized reaction conditions to carry out the cascade process (dba=dibenzylideneacetone, DavePhos=2-dicyclohexylphosphino-2'-N,N-dimethylaminobiphenyl).
  • The reaction proceeds with aryl, alkyl, and functionalized substitutents in both starting reactants.
  • The cyclization was also studied with N-substituted o-bromoanilines (which would give rise to N-substituted indoles); however, in this case, indole formation occurred only with 1-substituted-2-bromoalkenes.
  • Finally, the application of this methodology to o-chloroanilines required further optimization.
  • Although the catalyst based on DavePhos failed to promote the cascade process, a catalytic combination based on [Pd2(dba)3]/X-Phos promoted the formation of the indole ring also from the less reactive chloroanilines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685588.001).
  • [ISSN] 0947-6539
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Bartzatt R: Applying pattern recognition methods and structure property correlations to determine drug carrier potential of nicotinic acid and analogize to dihydropyridine. Eur J Pharm Biopharm; 2005 Jan;59(1):63-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nicotinic acid and dihydropyridine form ester groups on 10 beta-lactam antibiotics with an oxymethyl group forming a linkage between the antibiotic and the drug carrier (nicotinic acid or dihydropyridine).
  • Calculated molecular properties are analyzed by self-organizing tree algorithm (SOTA), bivariate regression, cluster analysis, factor analysis, discriminant analysis, hierarchical classification, and principal coordinates analysis.
  • Ten important pharmacological properties for each of the nicotinic acid and dihydropyridine antibiotic derivatives are numerically similar and highly correlated.
  • Calculated molecular properties include molar refractivity, molar volume, parachor, index of refraction, partition coefficient (log P), polarizability, and polar surface area.
  • Dermal permeabliity coefficients analyzed by hierarchical classification and SOTA analysis were shown to be closely interrelated and highly correlated.
  • Ten properties of the nicotinic acid and dihydropyridine were compared by Passing-Bablok regression analysis and shown to be highly correlated (r=0.9879).
  • Box plot analysis of 10 properties, inclusive of both groups of derivatives, showed narrow ranges in values.
  • Cluster analysis of derivative properties showed the nicotinic acid derivatives to be highly similar to the dihydropyridine derivatives of the same antibiotics.
  • Cluster analysis was performed by single linkage, complete linkage, and centroid linkage.
  • Factor analysis showed the nicotinic acid derivatives to be interrelated and similar to the dihydropyridine derivatives.
  • Discriminant analysis performed on all derivatives formed a single highly cohesive and non-differentiated cluster, demonstrating strong similarity among nicotinic acid and dihydropyridine derivatives.
  • Principal coordinates analysis (determines similarity) of Kp values showed high similarity between the nicotinic acid and dihydropyridine antibiotic derivatives.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567303.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dihydropyridines; 0 / Drug Carriers; 0 / Nicotinic Acids; 7M8K3P6I89 / 1,4-dihydropyridine
  •  go-up   go-down


70. Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Abu Ajaj K, Unger C, Warnecke A, Saleem T, El-Melegy N, Madkor H, Kratz F: Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer; 2010 Dec;46(18):3434-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unfortunately, whilst accumulating clinical data have suggested that taxanes may prolong the survival in a subset of men with prostate carcinoma, the dose and duration of administration of these drugs are limited by their significant systemic toxicities due to a lack of tumour selectivity.
  • In an attempt to improve both the water solubility and tumour-targeting properties of paclitaxel (Taxol®), we set out to develop a water soluble paclitaxel prodrug that is activated specifically by prostate-specific antigen (PSA) which is almost exclusively expressed in prostate tissue and prostate carcinoma making it an ideal molecular target for prodrug strategies.
  • Using albumin as a drug carrier, we describe a novel albumin-binding prodrug of paclitaxel, EMC-Arg-Ser-Ser-Tyr-Tyr-Ser-Leu-PABC-paclitaxel [EMC: ε-maleimidocaproyl; PABC: p-aminobenzyloxycarbonyl] that was synthesised by reacting EMC-Arg-Ser-Ser-Tyr-Tyr-Ser-OH with H-Leu-PABC-paclitaxel.
  • This prodrug was water soluble and was bound to endogenous and exogenous albumin.
  • Moreover, incubation studies with PSA demonstrated that the albumin-bound form of the prodrug was cleaved rapidly at the P1-P1' scissile bond releasing the paclitaxel-dipeptide H-Ser-Leu-PABC-paclitaxel.
  • Of note was that the albumin-bound form of the prodrug was approximately three-fold more active in killing PSA-positive LNCaP cells than paclitaxel.
  • The new paclitaxel prodrug (3 × 24 mg paclitaxel equivalents) showed comparable antitumour activity on the primary tumour to paclitaxel at its maximum-tolerated dose (3 × 12mg/kg), reduced circulating PSA levels and demonstrated a better antitumour effect on lung metastases but not on bone metastases.
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Drug Evaluation. Humans. Luminescence. Male. Maximum Tolerated Dose. Mice. Mice, SCID. Neoplasm Transplantation. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20933385.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Prodrugs; EC 3.4.21.77 / Prostate-Specific Antigen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


71. Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR: Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol; 2007 May;14(5):406-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
  • OBJECTIVE: To report the results from an Iranian large population-based randomized study of screening using prostate-specific antigen (PSA) to detect prostate cancer.
  • MATERIALS AND METHODS: A total of 3758 Iranian men older than 40 years were mass checked by PSA-based screening.
  • Men with an abnormal digital rectal examination (DRE) and serum total PSA level of greater than 4 ng/mL, underwent transrectal ultrasonography (TRUS)-guided extended prostate biopsy.
  • RESULTS: The PSA value (mean +/- standard deviation, SD) in all men without prostate cancer was 1.6 +/- 1.1 ng/mL and in those with cancer 18 +/- 44.8 ng/mL (P = 0.001).
  • PSA values increased with age.
  • In those aged 40-49, 50-59, 60-69 and > or = 70 years, the mean +/- SD PSA values were 1.3 +/- 0.7, 1.4 +/- 0.8, 1.8 +/- 1 and 2.2 +/- 1.6 ng/mL, respectively.
  • Among the screened men, 323 (8.6%) had a serum PSA concentration greater than 4 ng/mL.
  • Additionally, nine cancers were detected among 16 patients with PSA of less than 4 ng/mL who had a doubtful DRE finding.
  • CONCLUSIONS: The Iranian male population develops prostate cancer quite commonly if their serum PSA levels are greater than 4.0 ng/mL.
  • [MeSH-major] Mass Screening. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


72. Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH: Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol; 2007 Apr;51(4):931-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The stage and grade shift of currently diagnosed prostate cancer has led to a diminished prognostic power of the Gleason score system.
  • We investigated the predictive value of the amount of high-grade cancer (Gleason growth patterns 4/5) in the biopsy for prostate-specific antigen (PSA) and clinical relapse after radical prostatectomy.
  • METHODS: PSA-tested participants (N=281) of the European Randomized Study of Screening for Prostate Cancer (ERSPC) who underwent radical prostatectomy were analyzed.
  • Besides clinical features, and serum-PSA, histopathologic features as determined in the diagnostic biopsy and matching radical prostatectomy specimen were related to patient outcome.
  • RESULTS: At a median follow-up of 7 yr, 39 (13.9%), 24 (8.5%), and 12 (4.3%) patients had PSA >/=0.1 ng/ml, PSA >/=1.0 ng/ml, and clinical relapse after radical prostatectomy, respectively.
  • Using Cox proportional hazards, PSA level (p=0.002), length of tumour (p=0.040), and length of high-grade cancer (p=0.006) in the biopsy, but not Gleason score, were independent prognostic factors for biochemical relapse (PSA >/=0.1 ng/ml) when assessed as continuous variables.
  • In radical prostatectomies, the proportion of high-grade cancer (p<0.001) was most predictive of relapse (PSA >/=0.1 ng/ml).
  • For PSA >/=1.0 ng/ml and clinical relapse, the amount of high-grade cancer, both in the biopsy specimen (p=0.016 and p=0.004, respectively) and radical prostatectomy specimen (p=0.002 and p=0.005, respectively), but not Gleason score, was an independent predictor.
  • [MeSH-minor] Aged. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / epidemiology. Prognosis. Prostate-Specific Antigen / blood


73. Choi YD, Kang DR, Nam CM, Kim YS, Cho SY, Kim SJ, Cho IR, Cho JS, Hong SJ, Ham WS: Age-specific prostate-specific antigen reference ranges in Korean men. Urology; 2007 Dec;70(6):1113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The serum prostate-specific antigen (PSA) level varies widely among different races and increases with age.
  • In this study, we evaluated the variation in serum PSA levels in a multicenter study population to determine a standard age-specific PSA reference range for Korean men without clinically evident prostate cancer.
  • METHODS: We retrospectively analyzed 120,439 Korean men, ranging in age from 30 to 79 years, whose serum PSA levels were measured at one of eight referral hospitals from November 1998 to July 2005.
  • RESULTS: Our recommended age-specific reference ranges (95th percentile) of serum PSA levels for Korean men were 0.32 to 1.88 ng/mL for men 30 to 39 years, 0.30 to 1.92 ng/mL for men 40 to 49 years, 0.30 to 2.37 ng/mL for men 50 to 59 years, 0.31 to 3.56 ng/mL for men 60 to 69 years, and 0.30 to 5.19 ng/mL for men 70 to 79 years old.
  • The serum PSA level increased annually, corresponding to an increase of 0.0023 ng/mL for men in their 40s, 0.0175 ng/mL for men in their 50s, 0.0499 ng/mL for men in their 60s, and 0.0398 ng/mL for men in their 70s, with a steep increase for men in their 50s and the largest increase in men older than 60 years.
  • CONCLUSIONS: The results of our study have shown that the age-specific reference ranges (95th percentile) for serum PSA levels in Korean men are lower than those for white men.
  • Our newly proposed age-specific reference ranges from this multicenter study will be more valuable in the interpretation of PSA data for Korean men.


74. Kislyi KA, Samet AV, Strelenko YA, Semenov VV: Synthetic utilization of polynitroaromatic compounds. 6. Remarkable regioselectivity in nucleophilic displacement of aromatic nitro groups with amines. J Org Chem; 2008 Mar 21;73(6):2285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthetic utilization of polynitroaromatic compounds. 6. Remarkable regioselectivity in nucleophilic displacement of aromatic nitro groups with amines.
  • 5,7-Dinitroquinazoline-4-ones undergo nucleophilic displacement of a nitro group with N-, S-, and O-nucleophiles.
  • In contrast to previously studied dinitro-substituted benzoannulated five- and seven-membered heterocycles (where a high degree of selectivity was observed), these quinazolines mostly yield mixtures of regioisomeric substitution products.
  • At the same time, primary and secondary amines react selectively to afford 5-aminoquinazolones (peri-substitution).
  • A similar effect is observed for some other polynitroaromatic compounds with adjacent nitro and carbonyl groups.
  • This phenomenon is attributed to a stabilization of the intermediate peri-sigma-complex by intramolecular hydrogen bond N(+)-H...O double bond C.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302412.001).
  • [ISSN] 0022-3263
  • [Journal-full-title] The Journal of organic chemistry
  • [ISO-abbreviation] J. Org. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Hong SK, Han BK, Chung JS, Park DS, Jeong SJ, Byun SS, Choe G, Lee SE: Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int; 2008 Nov;102(9):1092-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, pathological stage (1997 pT2a vs pT2b) was not a significant predictor of BRFS in either uni- or multivariate analysis (P = 0.289 and P = 0.241, respectively).
  • Only preoperative serum PSA level and pathological Gleason score along with positive surgical margin were significant predictors of PSA outcome after RRP on multivariate analysis.
  • [MeSH-major] Neoplasm Staging / standards. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Prostate-Specific Antigen / blood. Retrospective Studies


76. Sardana G, Jung K, Stephan C, Diamandis EP: Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res; 2008 Aug;7(8):3329-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
  • The prostate specific antigen (PSA) test, in combination with digital rectal examination, is the gold standard for prostate cancer diagnosis.
  • Each cell line was cultured in triplicate, followed by a bottom-up analysis of the peptides by two-dimensional chromatography and tandem mass spectrometry.
  • Approximately, 12% (329) of the proteins identified were classified as extracellular and 18% (504) as membrane-bound among which were known prostate cancer biomarkers such as PSA and KLK2.
  • To select the most promising candidates for further investigation, tissue specificity, biological function, disease association based on literature searches, and comparison of protein overlap with the proteome of seminal plasma and serum were examined.
  • On the basis of this, four novel candidates, follistatin, chemokine (C-X-C motif) ligand 16, pentraxin 3 and spondin 2, were validated in the serum of patients with and without prostate cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Culture Media, Conditioned / chemistry. Prostatic Neoplasms / chemistry
  • [MeSH-minor] Bone Neoplasms / chemistry. Bone Neoplasms / secondary. Breast Neoplasms / chemistry. Cation Exchange Resins. Cell Line, Tumor. Chromatography, Liquid / methods. Computational Biology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Lymphatic Metastasis. Male. Prostate / chemistry. Prostate-Specific Antigen / blood. Proteomics. Reproducibility of Results. Tandem Mass Spectrometry

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18578523.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cation Exchange Resins; 0 / Culture Media, Conditioned; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


77. Santos FC, Leite RP, Custódio AM, Carvalho KP, Monteiro-Leal LH, Santos AB, Góes RM, Carvalho HF, Taboga SR: Testosterone stimulates growth and secretory activity of the female prostate in the adult gerbil (Meriones unguiculatus). Biol Reprod; 2006 Sep;75(3):370-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prostate of the female gerbil (Meriones unguiculatus) is similar to the human female prostate (Skene gland) and, despite its reduced size, it is functional and shows secretory activity.
  • Circulating levels of testosterone and estradiol were monitored, and the prostate and ovaries subjected to structural and immunocytochemical analyses.
  • Immunocytochemistry identified the expression of androgen receptor and a prostate-specific antigen (PSA)-related antigen in prostatic epithelial cells.
  • A circulating PSA-related antigen was also found, and its concentration showed strong negative correlation with circulating estrogen.
  • Analysis of the ovaries showed the occurrence of a polycystic condition and stromal cell hyperplasia.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707769.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; 3XMK78S47O / Testosterone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


78. Miller J, Perumalla C, Heap G: Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg; 2005 Jan-Feb;75(1-2):48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following data were recorded in a database: date of birth; digital rectal examination findings; serum prostate specific antigen (PSA); biopsy technique; number of cores taken; number of positive cores; Gleason grade and score; complications.
  • Results were tabulated and simple statistical analysis performed to compare both groups.
  • A review of medical literature supports a tranperineal approach to patients who will tolerate sepsis poorly, or who have a suspected inflammatory cause of their raised PSA.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15740517.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


79. Beinart G, Rini BI, Weinberg V, Small EJ: Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer; 2005 Jun;4(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This phase II trial was conducted to assess the prostate-specific antigen (PSA)-modulating effects of APC8015 in patients with androgen-dependent prostate cancer (ADPC) with biochemical progression.
  • PATIENTS AND METHODS: Patients with nonmetastatic recurrent disease as manifested by increasing PSA levels (0.4-6.0 ng/mL) and who had undergone previous definitive surgical or radiation therapy were enrolled.
  • Prostate-specific antigen was measured at baseline and monthly until disease progression, defined as a doubling of the baseline or nadir PSA value (whichever was lower) to > or = 4 ng/mL or development of distant metastases.
  • RESULTS: Thirteen of 18 patients demonstrated an increase in PSA doubling time (PSADT), with a median increase of 62% (4.9 months before treatment vs. 7.9 months after treatment; P = 0.09; signed-rank test).
  • APC8015 as single-agent immunotherapy for patients with ADPC and biochemical progression did not result in > or = 50% decrease in PSA from baseline levels but did appear to modulate PSADT in some patients.
  • [MeSH-minor] Aged. Disease Progression. Humans. Male. Middle Aged. Neoplasm Recurrence, Local


80. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D: Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):993-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the radiation dose-response relation of tumor control probability in low-risk and intermediate-risk prostate cancer patients treated with radiotherapy alone.
  • The low-risk patients had 1992 American Joint Committee on Cancer Stage T2a or less disease as determined by digital rectal examination, prostate-specific antigen (PSA) levels of < or =10 ng/mL, and biopsy Gleason scores of < or =6.
  • The intermediate-risk patients had one or more of the following: Stage T2b-c, PSA level of < or =20 ng/mL but >10 ng/mL, and/or Gleason score of 7, without any of the following high-risk features: Stage T3 or greater, PSA >20 ng/mL, or Gleason score > or =8.
  • The ASTRO PSA failure was defined as three consecutive PSA rises, with the time to failure backdated to the mid-point between the nadir and the first rise.
  • The second biochemical failure definition used was a PSA rise of > or =2 ng/mL above the current PSA nadir (CN + 2).
  • RESULTS: On the basis of the ASTRO definition, at 5 years after radiotherapy, the dose required for 50% tumor control (TCD(50)) for low-risk patients was 57.3 Gy (95% confidence interval [CI], 47.6-67.0).
  • Recursive partitioning analysis identified two subgroups within the low-risk group, as well as the intermediate-risk group: PSA level <7.5 vs. > or =7.5 ng/mL.
  • Most of the benefit from the higher doses for the low- and intermediate-risk group was derived from the patients with the higher PSA values.
  • Most of the benefit from the higher doses derived from low-risk patients with higher PSA levels.
  • Most of the benefit from the higher doses also derived from the intermediate-risk patients with higher PSA levels.


81. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI: A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol; 2010 May;66(1):181-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In arm II, five of eight patients (63%) had a >or=50% decline in prostate-specific antigen (PSA), including one patient whose disease had previously progressed on docetaxel.
  • Since preclinical studies suggest a dose-dependent effect of panobinostat on PSA expression, and other phase I data demonstrate that intravenous panobinostat produces higher peak concentrations (>20- to 30-fold) and area under the curve (3.5x-5x), a decision was made to focus the development of panobinostat on the intravenous formulation to treat CRPC.
  • [MeSH-minor] Acetylation / drug effects. Administration, Oral. Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Fluorodeoxyglucose F18. Histones / blood. Humans. Indoles. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Neoplastic Cells, Circulating / drug effects. Positron-Emission Tomography. Prostate-Specific Antigen / blood. Prostate-Specific Antigen / drug effects. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20217089.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / PC051382
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Hydroxamic Acids; 0 / Indoles; 0 / Taxoids; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 15H5577CQD / docetaxel; 9647FM7Y3Z / panobinostat; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


82. Loeb S, Roehl KA, Helfand BT, Catalona WJ: Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology; 2008 Oct;72(4):887-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: With the widespread use of prostate-specific antigen (PSA)-based screening, there is now concern about the overdiagnosis and overtreatment of men with low-risk prostate cancer (PCa).
  • METHODS: From a large RP database, we compared potency, continence, and complication rates among men meeting one of the following active monitoring criteria from the literature: clinically localized, Gleason score of 7 or less, and no significant comorbidities; T1b-T2b NOMO, Gleason score of 7 or less, and PSA of 15 ng/mL or less; and T1c PCa.


83. Suekane S, Noguchi M, Nakashima O, Yamada S, Kojiro M, Matsuoka K: Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy. Int J Urol; 2007 Aug;14(8):713-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pretreatment parameters of the serum prostate-specific antigen (PSA), the PSA density, the percentage of positive biopsy cores, the percentage of cancer length and the percentage of Gleason grade 4/5 cancer in the biopsy were determined and compared with the pathological features of prostate cancer in RP specimens.
  • All quantitative biopsy parameters were strongly predictive of the non-organ-confined status, the positive surgical margin and the seminal vesicle invasion in the logistic regression analysis.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Follow-Up Studies. Humans. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Prostate-Specific Antigen / blood. Retrospective Studies. Severity of Illness Index. Treatment Failure

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681061.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


84. Merrick GS, Galbreath RW, Butler WM, Waller KE, Allen ZA, Lief J, Adamovich E: Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer; 2007 Jul 15;110(2):289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent brachytherapy more than 3 years before analysis.
  • Of the 530 patients, 412 (77.7%) received supplemental external beam radiation therapy (XRT) and 177 (33.4%) received androgen deprivation therapy. bPFS was defined by a prostate-specific antigen (PSA) </=0.40 ng/mL after nadir.
  • Cox linear regression analysis demonstrated that clinical stage and radiation dose (D90) predicted for CSS, whereas pretreatment PSA, clinical stage, and prostate size predicted for bPFS.
  • [MeSH-minor] Aged. Cohort Studies. Disease Progression. Humans. Male. Survival Analysis


85. Georgiadis JR, Kortekaas R, Kuipers R, Nieuwenburg A, Pruim J, Reinders AA, Holstege G: Regional cerebral blood flow changes associated with clitorally induced orgasm in healthy women. Eur J Neurosci; 2006 Dec;24(11):3305-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracerebral markers of sexual performance and orgasm were rectal pressure variability (RPstd) and perceived level of sexual arousal (PSA).
  • Significant positive correlations were found between RPstd and rCBF in the left deep cerebellar nuclei, and between PSA and rCBF in the ventral midbrain and right caudate nucleus.
  • [MeSH-minor] Adult. Arousal / physiology. Brain Mapping. Cerebellar Nuclei / anatomy & histology. Cerebellar Nuclei / physiology. Cerebellar Nuclei / radionuclide imaging. Copulation / physiology. Down-Regulation / physiology. Female. Humans. Middle Aged. Neural Inhibition / physiology. Pelvic Floor / innervation. Pelvic Floor / physiology. Physical Stimulation. Positron-Emission Tomography. Prefrontal Cortex / anatomy & histology. Prefrontal Cortex / physiology. Prefrontal Cortex / radionuclide imaging. Somatosensory Cortex / anatomy & histology. Somatosensory Cortex / physiology. Somatosensory Cortex / radionuclide imaging. Temporal Lobe / anatomy & histology. Temporal Lobe / physiology. Temporal Lobe / radionuclide imaging. Ventral Tegmental Area / anatomy & histology. Ventral Tegmental Area / physiology. Ventral Tegmental Area / radionuclide imaging

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156391.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


86. Vianna LE, Lo Y, Klein RS: Serum prostate-specific antigen levels in older men with or at risk of HIV infection. HIV Med; 2006 Oct;7(7):471-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum prostate-specific antigen levels in older men with or at risk of HIV infection.
  • OBJECTIVES: The aim of the study was to determine the rate of, and factors associated with, elevated prostate-specific antigen (PSA) levels in older men with or at risk of HIV infection.
  • METHODS: Using a cross-sectional analysis, we interviewed 534 men > or =49 years old at risk for HIV infection on demographics, behaviours and medical history.
  • Laboratory testing included serum PSA level and HIV serology, and T-cell subsets for those who were HIV seropositive.
  • Elevated PSA level was defined as >4.0 ng/mL, and men with elevated PSA levels were referred for urological evaluation.
  • Twenty men (4%) had elevated PSA.
  • On univariate analysis, only older age was significantly associated with elevated PSA, and there was no significant difference in the number of men with elevated PSA between HIV-positive and HIV-negative men (nine of 310 vs 11 of 224; P = 0.28).
  • On multivariate analysis, older age remained the only variable associated with elevated PSA level [reference group < or =50 years; adjusted odds ratio (OR(adj)) 1.0 for age 51-60 years; OR(adj) 5.9 (95% confidence interval 1.2-30.1) for age > or =61 years] adjusted for HIV status, family history of prostate cancer, and androgen use.
  • CONCLUSIONS: Among older men, PSA levels increased with age but did not differ by HIV status.
  • The clinical use of PSA levels in older men currently do not need to be modified for those with HIV infection.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:89-94 [12505290.001]
  • [Cites] Urology. 2003 Dec 22;62(6 Suppl 1):3-12 [14706503.001]
  • [Cites] Prev Med. 2004 Feb;38(2):182-91 [14715210.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Apr;50(1):71-8 [15094160.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2):128-36 [15112144.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2):137-48 [15112145.001]
  • [Cites] Urol Clin North Am. 2004 May;31(2):219-26 [15123402.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):294-9 [15241826.001]
  • [Cites] J Urol. 2004 Aug;172(2):435-7 [15247698.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Natl Cancer Inst Monogr. 1977 Dec;47:121-6 [349400.001]
  • [Cites] J Urol. 1990 Jun;143(6):1146-52; discussion 1152-4 [1692885.001]
  • [Cites] Urol Int. 1990;45(5):290-2 [2219566.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] J Urol. 1995 Jan;153(1):158-60 [7966756.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):183-9 [7829213.001]
  • [Cites] N Engl J Med. 1996 Aug 1;335(5):345-6 [8663860.001]
  • [Cites] AIDS. 1996 Jun;10(7):797-8 [8805875.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1172-81 [9261620.001]
  • [Cites] Urology. 1998 Sep;52(3):428-32 [9730455.001]
  • [Cites] Semin Urol Oncol. 1998 Nov;16(4):187-92 [9858324.001]
  • [Cites] Urology. 2005 Jan;65(1):175 [15667896.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):563-72 [10591085.001]
  • [Cites] AIDS. 2000 Mar 31;14(5):553-9 [10780718.001]
  • [Cites] Lancet. 2000 May 27;355(9218):1886-7 [10866449.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1316-9 [11423263.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):547-53 [11709274.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):299-315 [11880206.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] AIDS. 2002 Aug 16;16(12):1703-4 [12172102.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • (PMID = 16925734.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA014998-05; United States / NIAID NIH HHS / AI / AI-051519; United States / NIDA NIH HHS / DA / DA014998-05; United States / NIAID NIH HHS / AI / P30 AI051519; United States / NIDA NIH HHS / DA / R01 DA014998; United States / NIDA NIH HHS / DA / R01 DA14998
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS49363; NLM/ PMC2435169
  • [Keywords] NOTNLM ; ageing / men's health / prostate / prostate-specific antigen
  •  go-up   go-down


87. Kravchick S, Bunkin I, Peled R, Yulish E, Ben-Dor D, Kravchenko Y, Cytron S: Patients with elevated serum PSA and indwelling catheter after acute urinary retention: prospective study of 63 patients with 7-year follow-up. J Endourol; 2007 Oct;21(10):1203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with elevated serum PSA and indwelling catheter after acute urinary retention: prospective study of 63 patients with 7-year follow-up.
  • BACKGROUND AND PURPOSE: Elevated PSA value in the presence of an indwelling catheter is still an enigma.
  • The aims of this prospective study were: to investigate the reliability of elevated PSA levels in patients with normal DRE and indwelling catheter after AUR; to assess the impact of preoperative TRUS-biopsy in detecting prostate cancer in such circumstances; to estimate the crucial duration of follow-up period.
  • PSA was assessed 5 days after catheter insertion.
  • Biopsies were taken when indicated by persistently elevated PSA or an abnormal DRE.
  • RESULTS: Mean PSA before catheter insertion differed significantly from PSA obtained on the 5(th) day after AUR (p = 0.001).
  • Mean PSA value in the follow-up period was significantly elevated in patients with carcinoma: 5.99 +/- 3.34 v/s 2.34 +/- 1.68 ng/ml (p = 0.007) and was the strongest predictor for cancer detection (p = 0.001).
  • Postoperative PSA level is the strongest predictor of cancer detection and could be usefully employed in these patients.
  • AUR and in the patients with large prostate cause elevated PSA.


88. Ross LE, Powe BD, Taylor YJ, Howard DL: Physician-patient discussions with african american men about prostate cancer screening. Am J Mens Health; 2008 Jun;2(2):156-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the study was to examine sociodemographic and other correlates of physician-patient discussions regarding the advantages and disadvantages of the prostate-specific antigen (PSA) test among African American men aged 40 or older.
  • A majority of African American men reported having discussed the advantages and disadvantages of prostate cancer screening and/or testing with their physicians before ordering it, and physician-patient discussions about the PSA test were associated with increased screening in African American men.
  • Inasmuch as African American men have greater prostate cancer incidence and mortality over other groups, future attempts should be made to find meaningful correlates of PSA screening and test use to help reduce the burden of this disease.
  • [MeSH-minor] Adult. Age Factors. Aged. Communication. Confidence Intervals. Cross-Sectional Studies. Educational Status. Health Education / organization & administration. Humans. Male. Men's Health. Middle Aged. Multivariate Analysis. Odds Ratio. Physician-Patient Relations. Prostate-Specific Antigen / blood. Risk Assessment. Socioeconomic Factors. Survival Analysis. United States / epidemiology


89. Roobol MJ, Schröder FH, Kranse R, ERSPC, Rotterdam: A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate; 2006 May 1;66(6):604-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA>or=3.0 ng/ml as biopsy indication.
  • MATERIALS AND METHODS: We compared predictors by means of descriptive statistics and logistic regression analysis in men (55-75 years) biopsied in either the 1st or 2nd screening round of ERSPC Rotterdam (interval 4 years).
  • RESULTS: Positive predictors for biopsy outcome in both screening rounds were an increased PSA level in the absence of a previous negative biopsy (PrevNB), DRE and TRUS suspicious and a positive family history (PFH).
  • Having had a PrevNB at initial screening strongly reduced the chance of cancer detection at repeat screening and in addition canceled the predictive potential of PSA.
  • CONCLUSION: If "detecting prostate cancer efficiently" were the aim, this study indicates that a "PSA only based biopsy threshold" may be replaced by another criterion incorporating, e.g., DRE, TRUS and prostate volume in men who were biopsied in the preceding 4 year interval.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Prostate 66:604-612, 2006. (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16388508.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


90. Takahashi Y, Hursting SD, Perkins SN, Wang TC, Wang TT: Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Mol Carcinog; 2006 Jan;45(1):18-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genistein strongly suppressed basal expression of androgen-responsive gene (ARG) mRNAs, including prostate-specific antigen (PSA) and Ste20-related proline-alanine-rich kinase (SPAK).
  • Culturing LNCaP cells in the presence of the synthetic androgen R1881-induced increases in PSA, SPAK, B2M, and SEPP1 mRNA levels.
  • For PSA and SPAK, genistein also blocked or downregulated 17beta-estradiol-induced increases in mRNA expression.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Male. Metribolone / pharmacology. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / pathology. Prostatic Neoplasms / prevention & control. RNA, Messenger / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16299812.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogens; 0 / RNA, Messenger; 2C323EGI97 / Metribolone; DH2M523P0H / Genistein; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


91. Jiménez JA, Li X, Zhang YP, Bae KH, Mohammadi Y, Pandya P, Kao C, Gardner TA: Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Ther; 2010 Mar;17(3):180-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we analyzed the preclinical utility and antitumor efficacy of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) delivered by Ad-IU2, a prostate-specific replication-competent adenovirus (PSRCA), against androgen-independent prostate cancer.
  • Through transcriptional control of adenoviral early genes E1a, E1b and E4, as well as TRAIL by two bidirectional prostate-specific enhancing sequences (PSES), the expression of TRAIL and adenoviral replication was limited to prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA)-positive cells.
  • Ad-IU2 induced fivefold greater apoptosis selectively in PSA/PSMA-positive CWR22rv and C4-2 cells than an oncolytic adenoviral control.
  • Ad-IU2 showed superior killing efficiency in PSA/PSMA-positive prostate cancer cells at doses five- to eight-fold lower than required by a PSRCA to produce a similar effect; however, this cytotoxic effect was not observed in non-prostatic cells.
  • In vivo, Ad-IU2 markedly suppressed the growth of subcutaneous androgen-independent CWR22rv xenografts compared with a PSRCA at 6 weeks after treatment (3.1- vs 17.1-fold growth of tumor).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] J Virol. 1998 Dec;72(12):9470-8 [9811680.001]
  • [Cites] Hum Gene Ther. 1999 Jul 1;10(10):1721-33 [10428217.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9 [10462204.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4200-3 [10485454.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1153-62 [15555548.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):165-86 [15389801.001]
  • [Cites] Cancer Gene Ther. 2005 Mar;12(3):228-37 [15550937.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1941-51 [15753394.001]
  • [Cites] J Urol. 2005 Aug;174(2):553-6; discussion 556 [16006890.001]
  • [Cites] Cancer Gene Ther. 2006 Feb;13(2):159-68 [16082383.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5224-30 [16951242.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Hum Gene Ther. 2000 Jan 1;11(1):139-49 [10646646.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):798-806 [10741699.001]
  • [Cites] Nat Med. 2000 May;6(5):564-7 [10802713.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25065-8 [10862756.001]
  • [Cites] Nat Med. 2001 Jan;7(1):94-100 [11135622.001]
  • [Cites] Nat Med. 2001 Feb;7(2):240-3 [11175857.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10767-74 [11278284.001]
  • [Cites] Nat Med. 2001 Apr;7(4):383-5 [11283636.001]
  • [Cites] Hum Gene Ther. 2001 Jul 1;12(10):1343-52 [11440627.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6012-9 [11507044.001]
  • [Cites] Mol Ther. 2001 Sep;4(3):257-66 [11545617.001]
  • [Cites] Urol Clin North Am. 2001 Aug;28(3):555-65 [11590814.001]
  • [Cites] Cancer Gene Ther. 2002 Feb;9(2):164-72 [11857034.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3084-92 [12036918.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3199-205 [12149291.001]
  • [Cites] Mol Ther. 2002 Sep;6(3):415-21 [12231179.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6165-71 [12414643.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):496-509 [15093180.001]
  • [Cites] J Interferon Cytokine Res. 2004 Apr;24(4):219-30 [15144568.001]
  • [Cites] Prostate. 2004 Sep 15;61(1):35-49 [15287092.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40 [4625049.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] N Engl J Med. 1989 Aug 17;321(7):419-24 [2503724.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):406-12 [8169003.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12687-90 [8663110.001]
  • [Cites] Hum Gene Ther. 1996 Jan 20;7(2):215-22 [8788172.001]
  • [Cites] Science. 1996 Oct 18;274(5286):373-6 [8832876.001]
  • [Cites] Science. 1997 Apr 4;276(5309):111-3 [9082980.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2559-63 [9205053.001]
  • [Cites] Science. 1997 Aug 8;277(5327):815-8 [9242610.001]
  • [Cites] Immunity. 1997 Dec;7(6):813-20 [9430226.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14363-7 [9603945.001]
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1036-42 [9761805.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • (PMID = 19798123.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F31 CA106215-01; United States / NCI NIH HHS / CA / F31 CA106215; United States / NCI NIH HHS / CA / CA074042-11; United States / NCI NIH HHS / CA / R01 CA074042; United States / NCI NIH HHS / CA / R01 CA074042-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS131156; NLM/ PMC2821463
  •  go-up   go-down


92. Wang W, John EM, Ingles SA: Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev; 2005 Dec;14(12):2990-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a population-based case-control study of 488 African-American women (239 cases and 249 controls), we examined this polymorphism along with a polymorphism (-158 G/A) in an androgen-regulated gene (PSA) whose expression has been correlated with breast cancer prognosis.
  • There was no significant association between the PSA gene polymorphism and breast cancer risk, nor was there significant gene-gene interaction.
  • Our data, however, are unable to provide evidence that PSA is the pathway through which the protective effect of androgens operates.


93. Agalliu I, Weiss NS, Lin DW, Stanford JL: Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control; 2007 Nov;18(9):931-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
  • BACKGROUND: Although prostate cancer screening by measurement of serum prostate-specific antigen (PSA) and digital rectal examination (DRE) is common in clinical practice, the impact of such screening on prostate cancer-specific mortality remains uncertain.
  • METHODS: Data from a population-based case-control study in King County, Washington, among men aged 50-64 years (706 cases, 645 controls) were used to examine the relationships between PSA and DRE screening and fatal prostate cancer and other-cause mortality.
  • The screening variable used in this analysis was self-reported receipt of one or more PSA and/or DRE tests performed as part of a routine checkup in the five-year period before diagnosis or reference date.
  • RESULTS: A smaller proportion of men with fatal prostate cancer had one or more PSA and/or DRE screening tests compared to controls, resulting in an adjusted odds ratios (OR) of 0.38 (95% CI 0.19-0.77).
  • There was no association, however, between PSA and/or DRE screening and other-cause mortality (OR = 1.02; 95% CI 0.51-2.02).
  • CONCLUSIONS: Results of this study suggest a reduction in prostate cancer-specific mortality associated with PSA and/or DRE screening in middle-aged men.
  • Further, the study was not able to separate the relative efficacy of PSA versus DRE screening.
  • [MeSH-major] Mass Screening / methods. Palpation / methods. Prostate-Specific Antigen. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / mortality
  • [MeSH-minor] Case-Control Studies. Confidence Intervals. Humans. Interviews as Topic. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Rectum. Retrospective Studies. Survival Analysis


94. Morán Pascual E, Dicapua Sacoto C, Trassierra Villa M, Pontones Moreno JL, Ruiz Cerdá JL, Jiménez Cruz JF: [Watchful waiting in incidental adenocarcinoma of the prostate]. Actas Urol Esp; 2010 Nov;34(10):854-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Actitud expectante en el adenocarcinoma incidental de próstata.
  • MATERIAL AND METHODS: We included patients with PSA< 4 ng/mL or higher with previous negative biopsy, who underwent surgery for BPH being diagnosed of incidental prostate adenocarcinoma.
  • We performed a descriptive and retrospective study in patients with this diagnosis between 1992 and 2007.
  • Statistical analysis was performed using SPSS program.
  • Progression variables were: age, preoperative and postoperative PSA, stage, Gleason score, prostate volume, initial treatment, PSA evolution and salvage treatment if necessary.
  • Postoperative PSA and Gleason score showed up as prognostic variables of progression in T1a stage and postsurgery PSA did so in T1b patients.
  • Postoperative PSA and Gleason score can predict progression in T1a stage and postoperative PSA in T1b stage.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159280.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


95. Chavan SV, Maitra A, Roy N, Patwardhan S, Chavan PR: Genetic variants in the distal enhancer region of the PSA gene and their implication in the occurrence of advanced prostate cancer. Mol Med Rep; 2010 Sep-Oct;3(5):837-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variants in the distal enhancer region of the PSA gene and their implication in the occurrence of advanced prostate cancer.
  • In this study, we examined variants in the prostate specific antigen (PSA) gene and their possible association with the risk of prostate cancer, the occurrence of advanced disease, and serum PSA levels.
  • Three functional single nucleotide polymorphisms (SNPs) in the enhancer region of the PSA gene, -5429T/G, -5412T/C and -4643A/G, were genotyped in 84 prostate cancer cases and 109 controls using the SNaPshotTM multiplex technique.
  • Between these two groups, two SNPs, -5429T/G and -5412T/C, were found to have statistically significant differences in PSA genotype frequencies.
  • The heterozygous genotype in the PSA gene conferred an increased risk of advanced prostate cancer.
  • Genotype-based serum PSA levels for each SNP were also observed to be similar (P>0.05).
  • Heterozygosity observed in the PSA gene enhancer region contributes substantially to the occurrence of advanced prostate cancer.
  • The identification of men at risk for advanced disease by PSA genotype may aid in determining the most effective therapeutic strategy, with the aim of improving the quality of life of patients.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21472323.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


96. Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK: Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol; 2010 Feb;21(2):312-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
  • Prostate-specific antigen (PSA) response was defined as > or = 50% post-therapy decline from baseline.
  • RESULTS: The pooled PSA response proportion was 69% [95% confidence interval (CI) 56% to 80%].
  • There was no evidence of differential PSA response by disease characteristics.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5261-8 [18794543.001]
  • [Cites] J Urol. 2002 Dec;168(6):2444-50 [12441936.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1842-8 [14584065.001]
  • [Cites] Acta Oncol. 2002;41(7-8):668-74 [14651212.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2592-8 [14669278.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Cancer. 1979 Nov;44(5):1553-62 [498029.001]
  • [Cites] Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1579-84 [574057.001]
  • [Cites] Cancer Treat Rep. 1986 Apr;70(4):541-2 [3698053.001]
  • [Cites] Drugs. 1989 Feb;37(2):162-90 [2649354.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2825-8 [8669872.001]
  • [Cites] Support Care Cancer. 1998 Sep;6(5):462-8 [9773464.001]
  • [Cites] Stat Med. 1999 Feb 15;18(3):321-59 [10070677.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):284-9 [15671557.001]
  • [Cites] Stat Med. 2005 Nov 30;24(22):3479-95 [15977302.001]
  • [Cites] Clin Genitourin Cancer. 2006 Sep;5(2):131-7 [17026801.001]
  • [Cites] Eur Urol. 2007 May;51(5):1252-8 [17208356.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6396-403 [17975152.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):44-53 [11134194.001]
  • (PMID = 19633053.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / 5P50CA9038; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2852201
  •  go-up   go-down


97. Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P, Kinnersley P, Griffiths J, Jones M, Williams J, Grol R, Elwyn G: Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. J Med Internet Res; 2010;12(3):e27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
  • BACKGROUND: Men considering the prostate specific antigen (PSA) test for prostate cancer, an increasingly common male cancer, are encouraged to make informed decisions, as the test is limited in its accuracy and the natural history of the condition is poorly understood.
  • The Web-based PSA decision aid, Prosdex, was developed as part of the UK Prostate Cancer Risk Management Programme in order to help men make such informed decisions.
  • OBJECTIVES: The aim of this study was to evaluate the effect of the Web-based PSA decision aid, Prosdex, on informed decision making.
  • Men aged 50 to 75 who had not previously had a PSA test were randomly allocated to two intervention and two control groups.
  • (1) knowledge of prostate cancer and PSA, (2) attitude toward PSA testing, (3) behavior using a proxy measure, intention to undergo PSA testing.
  • Decisional conflict and anxiety were also measured as was uptake of the PSA test.
  • Six months later, PSA test uptake was ascertained from general practitioners' records, and the online questionnaire was repeated.
  • Compared with the control group that completed the initial online questionnaire, men in the Prosdex group had increased knowledge about the PSA test and prostate cancer (U/mn 0.70; 95% CI 0.62 - 0.76); less favourable attitudes to PSA testing (U/mn 0.39, 95% CI 0.31 - 0.47); were less likely to undergo PSA testing (U/mn 0.40, 95% CI 0.32 - 0.48); and had less decisional conflict (U/mn 0.32, 95% CI 0.25 - 0.40); while anxiety level did not differ (U/mn 0.50, 95% CI 0.42 - 0.58).
  • After six months, PSA test uptake was lower in the Prosdex group than in the paper version and the questionnaire control group (P = .014).
  • Test uptake was also lower in the control group that did not complete a questionnaire than in the control group that did, suggesting a possible Hawthorne effect of the questionnaire in favour of PSA testing.
  • CONCLUSIONS: Exposure to Prosdex was associated with improved knowledge about the PSA test and prostate cancer.
  • Men who had a high level of knowledge had a less favourable attitude toward and were less likely to undergo PSA testing.
  • Prosdex appears to promote informed decision making regarding the PSA test.
  • [MeSH-minor] Aged. Attitude to Health. Great Britain. Health Knowledge, Attitudes, Practice. Humans. Internet / standards. Male. Middle Aged. Odds Ratio. Online Systems / standards. Physicians, Family. Prostatic Neoplasms / diagnosis. Risk Management. Social Support. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2008 Feb 25;168(4):363-9 [18299490.001]
  • [Cites] BMC Fam Pract. 2007;8:58 [17916259.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1320-8 [19297566.001]
  • [Cites] Health Expect. 2001 Jun;4(2):99-108 [11359540.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD001431 [12804407.001]
  • [Cites] BMJ. 2003 Sep 27;327(7417):736-40 [14512487.001]
  • [Cites] Patient Educ Couns. 1999 Jul;37(3):255-63 [14528551.001]
  • [Cites] Fam Pract. 2004 Aug;21(4):347-54 [15249521.001]
  • [Cites] Br J Clin Psychol. 1992 Sep;31 ( Pt 3):301-6 [1393159.001]
  • [Cites] Med Decis Making. 1995 Jan-Mar;15(1):25-30 [7898294.001]
  • [Cites] JAMA. 1996 Aug 28;276(8):637-9 [8773637.001]
  • [Cites] Health Technol Assess. 1997;1(2):i, 1-96 [9414541.001]
  • [Cites] Arch Fam Med. 1999 Jul-Aug;8(4):333-40 [10418541.001]
  • [Cites] Patient Educ Couns. 2005 Jul;58(1):13-26 [15950832.001]
  • [Cites] Stat Med. 2006 Feb 28;25(4):543-57 [16252269.001]
  • [Cites] BMJ. 2006 Aug 26;333(7565):417 [16908462.001]
  • [Cites] Patient Educ Couns. 2006 Nov;63(3):367-79 [16875796.001]
  • [Cites] Ann Fam Med. 2007 Mar-Apr;5(2):112-9 [17389534.001]
  • [Cites] J Med Internet Res. 2007;9(3):e21 [17627930.001]
  • [Cites] Am J Prev Med. 2007 Nov;33(5):428-434 [17950409.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1310-9 [19297565.001]
  • (PMID = 20693148.001).
  • [ISSN] 1438-8871
  • [Journal-full-title] Journal of medical Internet research
  • [ISO-abbreviation] J. Med. Internet Res.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN48473735
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2956331
  •  go-up   go-down


98. Han JH, Lee YT, Kwak KW, Ahn SH, Chang IH, Myung SC, Oh SY, Lee YS, Kim W, Jin YW, Choi TI, Sung SH: Relationship between insulin resistance, obesity and serum prostate-specific antigen levels in healthy men. Asian J Androl; 2010 May;12(3):400-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between insulin resistance, obesity and serum prostate-specific antigen levels in healthy men.
  • The purpose of this study was to determine the relationship between insulin resistance, obesity and serum prostate-specific antigen (PSA) levels in healthy men with serum PSA level below 4 ng mL(-1).
  • The men included in the study cohort were 11 827 healthy male employees of the Korea Hydro and Nuclear Power Co., LTD who had undergone medical checkups including fasting glucose, fasting insulin and serum PSA between January 2003 and December 2008.
  • Age-adjusted body mass index (BMI) was significantly increased according to increasing quartile of insulin resistance as determined by HOMA and QUICKI, respectively, in analysis of variance (ANOVA) test and Duncan's multiple comparison test (P < 0.001), but age-adjusted serum PSA concentration was significantly decreased according to increasing quartile of insulin resistance as determined by HOMA and QUICKI (P < 0.001).
  • Age, BMI, insulin resistance by HOMA or QUICKI were significantly independent variables to serum PSA level in a multivariate linear regression analysis (P < 0.001).
  • Insulin resistance was a significant independent variable to serum PSA level along with BMI.
  • Insulin resistance and BMI were negatively correlated with serum PSA level in healthy men.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Metabolism. 1991 Jan;40(1):101-4 [1984562.001]
  • [Cites] Diabetes. 1988 Dec;37(12):1595-607 [3056758.001]
  • [Cites] Diabetes Care. 1996 Oct;19(10):1138-41 [8886564.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Sep;63(3):239-50 [16117808.001]
  • [Cites] Circulation. 2005 Nov 15;112(20):3066-72 [16275870.001]
  • [Cites] J Urol. 2006 Oct;176(4 Pt 1):1524-7; discussion 1527-8 [16952672.001]
  • [Cites] JAMA. 2007 Nov 21;298(19):2275-80 [18029831.001]
  • [Cites] J Urol. 2008 Mar;179(3):886-90; discussion 890-1 [18207169.001]
  • [Cites] Urology. 2008 Oct;72(4):749-54; discussion 754-5 [18701153.001]
  • [Cites] Arch Med Res. 2008 Nov;39(8):803-8 [18996295.001]
  • [Cites] BJU Int. 2008 Nov;102(9):1097-101 [18522630.001]
  • [Cites] J Urol. 2009 Feb;181(2):567-72; discussion 572-3 [19084848.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10 [10902785.001]
  • [Cites] Diabetes Care. 2001 Apr;24(4):683-9 [11315831.001]
  • [Cites] Diabetes Care. 2004 Aug;27(8):1998-2002 [15277430.001]
  • [Cites] Am J Physiol. 1979 Sep;237(3):E214-23 [382871.001]
  • [Cites] Int J Obes. 1982;6(2):183-9 [6807859.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Diabetes. 1994 Feb;43(2):212-9 [8288045.001]
  • (PMID = 20305674.001).
  • [ISSN] 1745-7262
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC3739256
  •  go-up   go-down


99. Ide H, Nakashima J, Kono H, Kikuchi E, Nagata H, Miyajima A, Nakagawa K, Oya M: Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. Jpn J Clin Oncol; 2010 Feb;40(2):177-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In multivariate analysis, primary Gleason grade > or =4 and PSA doubling time (PSA-DT) <6 months were independent predictors.
  • The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT > or =6), high-risk group (Gleason grade > or =4 and PSA-DT <6) and intermediate-risk group (all others).
  • In the intermediate- and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level > or =2 at the initiation of HT.
  • Primary Gleason grade > or =4 and PSA-DT <6 months are independent predictors.


100. Misra S, Mahajan PV, Chen X, Kannikeswaran N: Safety of procedural sedation and analgesia in children less than 2 years of age in a pediatric emergency department. Int J Emerg Med; 2008 Sep;1(3):173-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although young age is considered a risk factor for adverse events related to procedural sedation and analgesia (PSA), data in very young children (<2 years of age) are lacking.
  • AIMS: The main objective of our study is to describe PSA in children <2 years of age in an inner city tertiary care pediatric emergency department (PED).
  • METHODS: We conducted a retrospective chart review from January 2005 to June 2007 of children <2 years of age who received PSA in our PED.
  • We collected demographic variables, indication for and medications used for PSA, adverse events (AE) related to PSA, and interventions performed to treat them.
  • RESULTS: Of the children who received PSA, 14.5% (180/1,235) were <2 years of age of whom 173 were included for the analysis; 73% (126/173) of the study subjects were between 1 and 2 years of age, 54.3% (94/173) were male, and 96.5% (167/173) belonged to American Society of Anesthesiologists class 1.
  • Incision and drainage (45.0%, 78/173) and laceration repair (32.4%, 56/173) were the two most common indications for PSA.
  • Ketamine and midazolam was the most common combination medication used for PSA (62.4%, 108/173).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Emerg Med. 2008 Mar;51(3):291-8 [18222564.001]
  • [Cites] Pediatr Emerg Care. 2007 Apr;23(4):218-22 [17438433.001]
  • [Cites] Pediatrics. 2006 Dec;118(6):2587-602 [17142550.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):1087-96 [16951002.001]
  • [Cites] Pediatrics. 2006 May;117(5):1511-8 [16651304.001]
  • [Cites] Ann Emerg Med. 2004 Nov;44(5):460-71 [15520705.001]
  • [Cites] Pediatrics. 2000 Mar;105(3):E42 [10699144.001]
  • [Cites] Anesth Analg. 1997 Dec;85(6):1207-13 [9390581.001]
  • [Cites] J Emerg Med. 2004 Jul;27(1):11-4 [15219297.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Nov;157(11):1090-6 [14609900.001]
  • [Cites] Ann Emerg Med. 2003 May;41(5):617-22 [12712027.001]
  • [Cites] Acad Emerg Med. 2002 Jun;9(6):609-12 [12045074.001]
  • [Cites] Pediatrics. 2002 Feb;109(2):236-43 [11826201.001]
  • [Cites] Ann Emerg Med. 1999 Oct;34(4 Pt 1):483-91 [10499949.001]
  • (PMID = 19384511.001).
  • [ISSN] 1865-1372
  • [Journal-full-title] International journal of emergency medicine
  • [ISO-abbreviation] Int J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2657272
  •  go-up   go-down






Advertisement